S&P 500 Financials Sector SEC Filings — March 03, 2026

03-03-2026

Select Medical Holdings Corporation (NYSE: SEM) entered a definitive merger agreement to be acquired by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS for $16.50 per share in cash, representing an enterprise value of $3.9B and premiums of 18% over the unaffected share price and 25% over the 90-day VWAP as of November 24, 2025. The transaction, unanimously approved by a special committee of independent directors, is expected to close mid-2026 subject to majority non-consortium shareholder approval, HSR antitrust clearance, and other regulatory approvals, with initial rollover participants owning 11.8% agreeing to vote in favor. While offering a significant premium, the deal carries risks including failure to secure approvals, potential termination fees, business disruptions, and stock price decline if not consummated.

• ·As of Dec 31, 2025, Select Medical had operations in 39 states and the District of Columbia.
• ·Merger not subject to financing condition; existing debt expected to remain outstanding.
• ·Advisors include Goldman Sachs and Skadden Arps (Special Committee), J.P. Morgan and Wells Fargo (Consortium debt financing), Dechert LLP (Select Medical).

03-03-2026

Microbot Medical Inc. issued a press release on March 3, 2026, confirming its continued operational and commercial stability amid current geopolitical events in the Middle East. The press release is furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. No financial impacts or disruptions were reported.

03-03-2026

Karyopharm Therapeutics Inc. entered into a Second Amendment to its Credit and Guaranty Agreement and a Forbearance Agreement on February 27, 2026, allowing deferral of certain principal and interest payments until September 2026 and maintaining a $10.0M minimum liquidity covenant through October 10, 2026, conditioned on raising at least $25.0M in equity proceeds by June 10, 2026. This aims to extend the liquidity runway beyond Q2 2026 and anticipated top-line data from the Phase 3 XPORT-EC-042 trial in mid-2026. However, the agreements do not waive defaults, effectiveness depends on the capital raise, and the filing notes substantial doubt about the company's ability to continue as a going concern.

• ·Prepayment premium of 5% extended through June 10, 2026, or to May 8, 2027 if Capital Raise Trigger met
• ·Forbearance on payment defaults under 2028 Notes and 2029 Notes until September 30, 2026
• ·Forbearance on liquidity covenant defaults until October 10, 2026
• ·Annual Report on Form 10-K for year ended December 31, 2025 filed February 13, 2026

03-03-2026

Hycroft Mining Holding Corp filed its 2025 Form 10-K on March 3, 2026, reporting a debt-free balance sheet with $181.7M in cash and cash equivalents (rising to $194.1M by Feb 28, 2026), a 55% increase in measured and indicated gold and silver resources to 16.4M oz gold and 562.6M oz silver, and a perfect safety record with 0.00 TRIFR over 1.4M work hours. The company eliminated a net profits royalty for $2.5M, launched a major 2025-2026 drill program (26,000m core + 8,200m RC), and achieved over 950% total shareholder return in 2025, while being added to the MSCI Small Cap Index. However, the Preliminary Economic Assessment (PEA) technical report has been delayed beyond Q1 2026 due to expanded resource scale requiring additional engineering.

• ·Robust metallurgical recoveries of over 82.8% for gold and 77.5% for silver using pressure oxidation for sulfide mineralization.
• ·Initial drill results at Vortex expanded the zone approximately 70 meters northwest and 90 meters down-dip west, remaining open in all directions.
• ·2026 plans include accelerating drilling on high-grade silver systems, testing new targets, completing trade-off analysis for pressure oxidation vs. roasting, and in-fill RC drilling for potential heap leach restart.
• ·PEA delay due to resource increase to over one billion tonnes, requiring mine plan updates, TSF redesign, and revised production profiles.

03-03-2026

Century Aluminum Company announced it will no longer rely on previously issued financial statements for fiscal years 2023 and 2024, and select 2024-2025 interim periods, due to a change from proportionate to full consolidation of Jamalco Production Assets following SEC Staff comments, resulting in restatements that increase total assets by $181M (2024) and $182M (2023), and total equity by $143M (2024) and $159M (2023), with no impact on net income attributable to Century stockholders. However, the change decreases gross profit by $13M (7%) in 2024 and $4.3M (4.7%) in 2023 due to higher depreciation, and the company expects to disclose a material weakness in internal controls. The 2025 Form 10-K, to be filed concurrently, will include the restated financials.

• ·Company acquired 55% interest in Jamalco in May 2023.
• ·Affected Financial Statements include interim periods ended March 31, 2024; June 30, 2024; September 30, 2024; March 31, 2025; June 30, 2025; and September 30, 2025.
• ·Q4 2025 Earnings Release on February 19, 2026 already reflects the Accounting Change.
• ·No impact on non-GAAP measures like adjusted EBITDA, debt covenants, or executive compensation.

03-03-2026

STAAR Surgical reported Q4 FY2025 net sales of $57.8 million, up 18.1% YoY driven by China growth, with gross margin expanding to 75.7% from 64.7% and adjusted EBITDA reaching breakeven versus a $20.8 million loss; however, ex-China sales declined 2.1% YoY to $40.3 million. Full FY2025 net sales dropped 23.7% YoY to $239.4 million despite 6.6% growth ex-China to $161.7 million, gross margin flat at 76.2%, and net loss widening to $80.4 million from $20.2 million, with adjusted EBITDA swinging to a $6.6 million loss from $23.2 million profit. The company appointed Warren Foust and Deborah Andrews as interim co-CEOs on February 2, 2026, and engaged Egon Zehnder for a permanent CEO search amid a terminated Alcon merger.

• ·Q4 FY2025 operating expenses $66.6M (up YoY) including $11.2M merger costs and $0.7M restructuring; ex-items $54.7M (-8.2% YoY).
• ·FY2025 operating expenses $274.1M (up YoY); ex-merger/restructuring $228.4M (-9.4% YoY).
• ·Share repurchase average price $17.20; $23.5M remaining under authorization as of January 2, 2026.
• ·No outstanding debt at FY2025 end.

03-03-2026

Byrna Technologies Inc. announced the retirement of CEO and Director Bryan Ganz, effective immediately, with Conn Davis appointed as successor CEO and new Director following an extensive search; Ganz will advise for up to six months to ensure a smooth transition. TJ Kennedy was elected Board Chair, succeeding Herbert Hughes who remains a Director. The announcement highlights Ganz's transformational leadership since 2019, growing revenues from $0.25M annually to a record $118M last year at an 84% CAGR, with 775,000 launchers sold worldwide and expansion to over 1,500 dealers.

• ·Bryan Ganz joined Board in 2016, became CEO in 2019; led uplisting to Nasdaq and Russell 2000 inclusion.
• ·TJ Kennedy previously CEO of Wrap Technologies (non-lethal devices) and President of FirstNet.
• ·Conn Davis previously EVP Strategy and Corporate Development at MasterBrand, Inc.
• ·Company plans to release preliminary fiscal Q1 2026 results consistent with normal cadence.
• ·Forbes named Byrna the 10th Most Successful Small Cap company in America last year.

03-03-2026

Aptera Motors Corp (SEV) announced on March 3, 2026, via press release that it has completed the first vehicle off its validation assembly line, marking a key production milestone. The disclosure was made under Regulation FD as Item 7.01 of the 8-K filing, with the press release attached as Exhibit 99.1.

03-03-2026

PMGC Holdings Inc. (ELAB) consummated Secured Pre-Paid Purchase #4 on February 6, 2026, under its existing equity purchase facility, with an original principal of $8.1M and purchase price of $7.5M, funded via allocations including $6.3M to a new subsidiary's controlled deposit account, $0.65M to placement agent Univest Securities LLC, $5K in legal fees, and $0.5M to the Company. The Investor can require issuance of Purchase Shares at 88% of the lowest VWAP over the prior 10 trading days (or cash if below $0.32), subject to a 9.99% ownership cap, with Company prepayment option at 120% and default penalties including 15% increase and 18% interest. A portion of Purchase Shares worth $1.2M was registered via prospectus supplement filed February 17, 2026.

• ·Deposit Account Control Agreement (DACA) grants Investor first-position security interest and control over funds upon instruction.
• ·Events of Default include failure to pay, insolvency, bankruptcy, judgments over $1M, and breaches of covenants.
• ·Equity facility originated from Securities Purchase Agreement dated September 23, 2025 (disclosed in 8-K filed September 29, 2025).

03-03-2026

A shareholder in COCA-COLA EUROPACIFIC PARTNERS plc (CCEP) has crossed or reached a threshold, resulting in a holding of 37.07% of voting rights attached to shares (with 0% through financial instruments), equivalent to 166,128,987 total voting rights. No position from previous notification is provided, indicating this may be a new or significantly updated stake.

• ·Filing date: March 03, 2026
• ·Filing type: 6-K (Foreign Issuer Report)

03-03-2026

Accel Entertainment reported record Q4 2025 revenue of $341.4 million, up 7.5% YoY from $317.5 million, and full-year 2025 revenue of $1.3 billion, up 8.1% YoY from $1.23 billion, driven by growth in locations to 4,501 (+2.2%) and gaming terminals to 27,950 (+2.9%). Adjusted EBITDA reached record $56.3 million in Q4 (+18.9% YoY) and $210.1 million for the year (+11.1% YoY), with net income surging 91.7% to $16.1 million in Q4 and 45.3% to $51.3 million annually. However, Illinois locations declined 2.5% to 2,705 and terminals fell 1.0% to 15,534, Nevada revenue dropped 5.0% YoY for the year to $108.9 million with hold-per-day down 11.5%, and net debt stood at approximately $311 million.

• ·Net cash provided by operating activities for YE 2025: $150.9 million, up 24.5% YoY
• ·Gross margin percentage improved to 31.72% in Q4 2025 from 30.41% in Q4 2024
• ·Louisiana revenue increased 75% YoY for YE 2025 to $37.6 million
• ·Georgia locations up 36.0% to 389 as of Dec 31, 2025
• ·New $900 million credit facility completed in September 2025, extending maturities to 2030

03-03-2026

Flotek Industries, Inc. announced on March 3, 2026, entry into an agreement to coordinate the installation of up to 50 megawatts of power generation and related support equipment linked to federal disaster recovery initiatives. The press release is attached as Exhibit 99.1 under Item 7.01. No financial impacts or performance metrics were disclosed.

03-03-2026

Community West Bancshares announced the retirement of Executive Vice President and Chief Operating Officer Blaine C. Lauhon, effective December 31, 2026, concluding his over 40-year banking career, including nearly a decade with the Bank since joining in 2017 via the Folsom Lake Bank acquisition. CEO James J. Kim highlighted Lauhon's leadership in operations, technology, and transformative initiatives, expressing gratitude for his contributions to the Bank's long-term success. No successor was named in the announcement.

• ·Lauhon named Chief Operating Officer in December 2024, Chief Administrative Officer in April 2024, Chief Banking Officer in 2021, Executive Vice President and Market Executive in 2019, and Senior Vice President and Senior Credit Officer in 2017.
• ·Bank headquartered in Fresno, California, established in 1979, first Banking Center opened January 10, 1980.
• ·Full board: Daniel J. Doyle (Chairman), Robert H. Bartlein (Vice Chairman), James J. Kim, Martin E. Plourd, Andriana D. Majarian, Suzanne M. Chadwick, Daniel N. Cunningham, Tom L. Dobyns, F.T. “Tommy” Elliott IV, Robert J. Flautt, James W. Lokey, Steven D. McDonald, Dorothea D. Silva, William S. Smittcamp, Kirk B. Stovesand; Louis C. McMurray (Director Emeritus).

03-03-2026

On March 3, 2026, MarineMax, Inc. held its Annual Meeting where shareholders elected William Brett McGill, Odilon Almeida, and Daniel Schiappa as directors for three-year terms expiring in 2029, with vote tallies showing majority support but opposition ranging from 2.2M to 4.3M shares against each nominee. Shareholders also approved an advisory say-on-pay vote (13.8M for vs. 1.5M against), an amendment to the 2021 Stock-Based Compensation Plan increasing available shares by 415,000, and ratification of KPMG LLP as auditors for the fiscal year ending September 30, 2026 (19.5M for vs. 0.2M against). All proposals passed with the required majorities.

• ·Proposal 1 votes: William Brett McGill (13,942,834 For, 4,266,909 Against, 2,942 Abstain); Odilon Almeida (15,866,497 For, 2,300,069 Against, 46,119 Abstain); Daniel Schiappa (16,016,030 For, 2,190,405 Against, 6,250 Abstain).
• ·Proposal 2 (say-on-pay): 13,838,107 For, 1,536,192 Against, 2,838,386 Abstain.
• ·Proposal 3 (Plan amendment): 13,732,171 For, 1,627,312 Against, 2,853,202 Abstain.
• ·Proposal 4 (auditor ratification): 19,511,049 For, 205,500 Against, 904,493 Abstain.
• ·Definitive Proxy Statement filed January 21, 2026.

03-03-2026

CNL Healthcare Properties, Inc. conducted a webinar on March 3, 2026, providing a company update and sharing views on the seniors housing market. The investor presentation was furnished as Exhibit 99.1 under Item 7.01. The filing explicitly states no admission of materiality and the information is not deemed filed under the Exchange Act.

03-03-2026

Reinsurance Group of America, Incorporated completed the offering of $400 million aggregate principal amount of 6.375% Fixed-Rate Reset Subordinated Debentures due 2056 on March 3, 2026, receiving net proceeds of approximately $396 million after underwriting discounts for general corporate purposes, including refinancing debt obligations. The debentures are unsecured subordinated obligations, bearing fixed interest at 6.375% per annum until September 15, 2036, then resetting based on the Five-Year Treasury Rate plus 2.344%, with semi-annual payments starting September 15, 2026, and maturing on September 15, 2056. They rank junior to senior indebtedness but pari passu with certain existing subordinated debentures like RZB and RZC.

• ·Debentures issued pursuant to Base Indenture dated August 21, 2012, supplemented by Twelfth Supplemental Indenture dated March 3, 2026.
• ·Public offering price: 100% of principal amount.
• ·Redemption options include par during Par Call Periods (three months prior to Reset Dates), make-whole otherwise, 100% for Tax Event or Regulatory Capital Event, and 102% for Rating Agency Event.
• ·Underwriting Agreement dated February 24, 2026.

03-03-2026

i3 Verticals, Inc. held its 2026 Annual Meeting of Stockholders on March 3, 2026, with 28,382,815 shares present, representing 91.6% of outstanding Common Stock as of the January 2, 2026 record date. All eight director nominees were elected with strong majorities (For votes ranging from 24.4M to 26.0M), though Elizabeth Seigenthaler Courtney received the highest withheld votes at 1,785,903; Deloitte & Touche LLP was ratified as auditors for the fiscal year ending September 30, 2026 with near-unanimous support (99.5% For); and executive compensation was approved on an advisory basis (98.3% For).

• ·Director vote details: Gregory Daily (For: 25,967,528; Withheld: 215,367); Clay Whitson (For: 26,011,532; Withheld: 171,363); Elizabeth Seigenthaler Courtney (For: 24,396,992; Withheld: 1,785,903); John Harrison (For: 25,443,942; Withheld: 738,953); Decosta Jenkins (For: 26,019,856; Withheld: 163,039); Timothy McKenna (For: 25,827,859; Withheld: 355,036); David Morgan (For: 25,431,093; Withheld: 751,802); David Wilds (For: 25,985,663; Withheld: 197,232)
• ·Auditor ratification: Against 145,375; Abstain 604
• ·Say-on-pay: Against 442,168; Abstain 3,317

03-03-2026

Evolus reported fourth quarter 2025 total net revenue of $90.3 million, up 14% YoY, and full-year 2025 revenue of $297.2 million, up 12% YoY for the sixth consecutive year of double-digit growth, with Q4 achieving GAAP operating income of $4.2 million. However, full-year GAAP operating loss was $32.7 million, a slight improvement from $34.4 million in 2024, while non-GAAP operating loss widened to $9.4 million from $0.3 million income, reflecting higher non-GAAP operating expenses of $209.7 million versus $185.0 million prior year. For 2026, the company guides revenue growth of 10-13% to $327-337 million but with non-GAAP operating expenses growing 0-3% to $210-216 million.

• ·U.S. account penetration above 55%; customer reorder rates approximately 71%.
• ·Evolysse™ and Estyme® expected to contribute 10-12% of 2026 revenue.
• ·Cash increased to $53.8M as of Dec 31, 2025 from $43.5M at Sep 30, 2025.
• ·Evolysse™ subject to 10% tariff, potential additional 5%; Jeuveau® not impacted by tariffs.
• ·2028 outlook: revenue $450-500M (15-19% 3-year CAGR), adjusted EBITDA margins 13-15%.

03-03-2026

Horizon Technology Finance reported Q4 2025 net investment income (NII) of $8.3M ($0.18 per share), down 20% YoY from $10.4M ($0.27 per share), and full-year NII of $44.4M ($1.05 per share), down 7% from $47.8M ($1.32 per share), driven by lower total investment income and a smaller debt portfolio. While debt portfolio yield was solid at 14.3% in Q4 (vs 14.9% prior) and 15.8% for FY (up from 15.6%), total portfolio shrank to $647.2M from $697.9M YoY, NAV per share fell 17% to $6.98, and net realized losses widened to $23.3M in Q4. The company ended with $154M committed backlog, funded $102.5M in new loans, and maintains strong liquidity with $142.7M cash.

• ·Weighted average credit rating of loan portfolio improved slightly to 2.9 from 3.1 YoY, but lower-rated loans (rating 1 and 2) increased to 13.1% of debt portfolio from 9.2%.
• ·Four debt investments rated 1 with fair value $24.5M (4.1% of debt portfolio).
• ·Net debt to equity leverage ratio 105% (below 120% target); asset coverage ratio 167%.
• ·Monthly distributions of $0.06 per share declared for April, May, June 2026.
• ·Post-quarter: Funded $30M to Pelthos Therapeutics (Jan 12, 2026) and $20M to Ossio (Jan 20, 2026).

03-03-2026

Haemonetics Corporation repaid in full its outstanding 0.00% Convertible Senior Notes due 2026 on March 2, 2026, paying an aggregate $300 million in cash representing the principal amount. The repayment was funded by cash on hand and borrowings under the company's revolving credit facility, with no holders exercising conversion rights and related capped call transactions expiring at maturity.

• ·Filing date: March 3, 2026
• ·Repayment date (earliest event): March 2, 2026

03-03-2026

Tonix Pharmaceuticals Holding Corp. (TNXP) received Nasdaq approval to uplist its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective at market open on March 3, 2026. This transition reflects compliance with higher financial and corporate governance standards, potentially boosting visibility, liquidity, and institutional investor access. CEO Seth Lederman described the uplisting as a key milestone to drive shareholder value.

• ·TONMYA is the first new fibromyalgia treatment in over 15 years.
• ·Company's 10-K for year ended December 31, 2024, filed March 18, 2025.

03-03-2026

RAPT Therapeutics, Inc. announced the final results of the tender offer by Redrose Acquisition Co., a wholly-owned subsidiary of GlaxoSmithKline LLC (indirectly GSK plc), which expired on March 2, 2026, with 30,137,567 shares (93.36% of outstanding shares) validly tendered, satisfying the minimum condition. All tendered shares were accepted for payment at $58.00 per share in cash. The merger is expected to complete on March 3, 2026, making RAPT a wholly-owned subsidiary of Parent, with shares to be delisted from Nasdaq Global Select Market.

• ·Offer and withdrawal rights expired one minute past 11:59 P.M., Eastern Time, on March 2, 2026.
• ·Merger without stockholder vote under Section 251(h) of the DGCL.
• ·Termination of Exchange Act registration and suspension of reporting obligations planned promptly after merger.
• ·CUSIP Number: 75382E208

03-03-2026

Versus Systems Inc. announced the renewal of its partnership with the Texas Rangers for the Filter Fan Cam product, extending through the 2026 Major League Baseball season and building on a successful five-year collaboration. The agreement introduces next-generation enhancements, including a high-performance C++ tracking engine, 60 frames per second camera driver, improved facial tracking, and dynamic face paint filters to boost fan engagement and create revenue opportunities. No financial terms or metrics were disclosed.

• ·Deployment at Globe Life Field during Texas Rangers home games.
• ·Filing date: March 3, 2026

03-03-2026

Knightscope, Inc. (NASDAQ: KSCP) completed the acquisition of Event Risk LLC, a nationwide provider of armed/unarmed security guarding and executive protection services with consistent double-digit growth, positive EBITDA, and strong Fortune 1000 client relationships. The transaction combines Event Risk's licensed response capabilities with Knightscope's autonomous robotics and AI platforms to create a unified managed security service model, enabling participation in guarding-required RFPs and increasing deployment density/recurring revenue. No specific deal terms or financial impacts were disclosed beyond cash, stock, and contingent consideration.

• ·Lake Street Capital Markets, LLC served as exclusive advisor to Knightscope.
• ·Plans to present integrated security model at GSX conference in Atlanta, Georgia later in 2026.
• ·Intends to evaluate additional acquisitions to expand managed service capabilities.

03-03-2026

On March 2, 2026, Slam Corp., a shell company, experienced a change in control when Digital Investment Strategy, LLC acquired 100% of the equity interests in Slam Sponsor, LLC, gaining indirect control over the company's Class A ordinary shares, Class B ordinary shares, Private Placement Warrants, and board appointment rights. Concurrently, directors Alex Rodriguez (also CEO), Himanshu Gulati, Lisa Harrington, Reggie Hudlin, Julian Nemirovsky, and Alexandre Zyngier resigned, along with CEO Alex Rodriguez and CFO Ryan Bright, with no disagreements noted; new directors Maulin Shah (Executive Chairman), Joseph Buttram (CEO), Raoul Scott (CFO), Karen Snow, Michael Frisch, Kain Warwick, and Ryan Bright were appointed, bringing expertise in investment management, cryptocurrency, and DeFi. No changes to the company's operations or prior disclosures occurred.

• ·Resignations and appointments effective March 2, 2026; no arrangements likely to result in future change of control per Regulation S-K Item 403(c)
• ·New directors/officers have no material interest in transactions under Item 404(a); entered standard indemnification agreements
• ·Prior filings referenced include Form 10-K for year ended Dec 31, 2024, 10-Q for Q1 2025 ended Mar 31, 2025, and multiple 8-Ks through Jan 30, 2026

03-03-2026

Viper Energy, Inc. filed an 8-K on March 3, 2026, providing an updated unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025, giving effect to the Sitio Acquisition (consummated August 19, 2025) and Endeavor Drop-Down (consummated May 1, 2025) as if each occurred on January 1, 2025. The filing also includes a press release dated March 2, 2026, announcing the launch of a secondary common stock offering by Diamondback Energy, Inc., EnCap Energy Capital Fund X, L.P., and Tumbleweed Royalty IV, LLC. No specific financial metrics from the pro forma are detailed in the filing body.

• ·Sitio Acquisition agreement dated June 2, 2025; amended 8-K on August 25, 2025
• ·Endeavor Drop-Down agreement dated January 30, 2025; prior 8-K filed May 5, 2025
• ·Exhibit 99.1: Press release dated March 2, 2026
• ·Exhibit 99.2: Pro forma for year ended December 31, 2025

03-03-2026

Skyworks Solutions CEO Phil Brace highlighted strong execution with four consecutive quarters of beat and raise, trajectory improvement in content at largest customer Apple, and the historic Qorvo acquisition enhancing GaN and RF capabilities for long-term growth in wireless tech through 2030. However, he noted ongoing challenges including flattish Apple content (stabilization rather than growth), prior loss of half a key socket to Broadcom, inflationary input costs like gold and PCBs, and external overhangs such as memory shortages and tariffs. Overall, Brace expressed optimism tempered by caution, emphasizing technology leadership amid a hyper-competitive market.

• ·Skyworks maintaining low inventory and monitoring book-to-bill amid potential memory shortages.
• ·No price concessions requested by smartphone customers despite memory cost pressures.
• ·Apple shifting to internal modem platform, providing ecosystem clarity.

03-03-2026

Flowco Holdings Inc. (NYSE: FLOC) completed its acquisition of Valiant Artificial Lift Solutions, LLC on March 3, 2026, for total consideration of approximately $200 million net of Valiant's cash, comprising $170 million in net cash funded by its ABL facility and 1.5 million shares of Class A common stock. The deal enhances Flowco's artificial lift portfolio with Valiant's ESP capabilities, enabling earlier well support and expanded presence in the Permian and other basins. CEO Joe Bob Edwards emphasized the cultural alignment and strategic synergies for delivering optimized solutions.

• ·Funded using available capacity under ABL facility
• ·Share amount originally determined based on 10-day volume-weighted average price as of January 30, 2026
• ·References Risk Factors in Form 10-K for fiscal year ended December 31, 2025

03-03-2026

Protagenic Therapeutics, Inc. appointed William (Bill) Nichols, Jr., age 51, as President effective February 3, 2026. Mr. Nichols brings senior commercial leadership experience from bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb. Compensation includes an annual base salary of $350,000, eligibility for a 40% target bonus, and an option grant equal to approximately 1.0% of the company's fully diluted shares.

• ·No arrangements or understandings with other persons for Mr. Nichols' selection as officer.
• ·No family relationships between Mr. Nichols and any directors or executive officers.
• ·No transactions involving Mr. Nichols requiring disclosure under Item 404(a) of Regulation S-K.

03-03-2026

Mobix Labs, Inc. filed an 8-K on March 3, 2026, attaching its Amended and Restated Bylaws (Exhibit 3.1), which detail governance rules for stockholder meetings. The bylaws specify that special meetings can be called by the Board, Chairperson, CEO, President, or Qualified Stockholders holding at least 10% voting power (with requests subject to 30-90 day windows relative to annual meetings), while annual meetings may be held or postponed by the Board if required by law. Quorum requires one-third of voting power, with notice periods of 10-60 days and other procedural rules outlined.

• ·Special meeting requests must be delivered not earlier than 30 days after annual meeting and not later than 90 days prior to next annual meeting.
• ·Notice of meetings given 10-60 days in advance.
• ·Quorum at stockholder meetings: presence of holders of one-third voting power.
• ·Proxies valid up to 3 years unless specified otherwise.
• ·Record date for notice: not more than 60 nor less than 10 days before meeting.

03-03-2026

News Corporation disclosed under Item 8.01 that, as part of its ongoing $1 billion stock repurchase program for Class A and Class B common stock, it provided daily transaction information to the Australian Securities Exchange (ASX) as required. Exhibits 99.1 and 99.2 contain the specific disclosures made on respective dates noted therein. The filing includes forward-looking statements on potential repurchases, subject to market conditions and other factors.

• ·Date of earliest event reported: March 2, 2026
• ·Filing Date: March 3, 2026
• ·Securities registered: Class A Common Stock (NWSA, par value $0.01) and Class B Common Stock (NWS, par value $0.01) on Nasdaq Global Select Market
• ·Company address: 1211 Avenue of the Americas, New York, New York 10036
• ·Registrant details: Delaware incorporation, Commission File Number 001-35769, IRS Employer ID 46-2950970

03-03-2026

Cal-Maine Foods, Inc. (CALM) announced the acquisition of shell egg, egg products, and prepared foods assets from Creighton Brothers LLC, including Crystal Lake LLC, for approximately $130 million, subject to customary post-closing adjustments. The transaction is funded entirely with available cash on hand. No prior period comparisons or financial impacts were disclosed in the filing.

• ·Acquisition announced on March 2, 2026
• ·Press release attached as Exhibit 99.1

03-03-2026

Stardust Power Inc. filed a 424B4 prospectus registering up to 2,000,000 shares of common stock (par value $0.0001) for resale by B. Riley Principal Capital II, LLC under a Common Stock Purchase Agreement dated February 12, 2026, enabling the company to elect sales of common stock for up to $10M aggregate gross proceeds. The company will not receive proceeds from the selling stockholder's resales but bears registration expenses, including legal and accounting fees. Common stock traded on Nasdaq under SDST closed at $3.43 on February 27, 2026; no performance declines noted as this is a financing facility disclosure.

• ·One-for-ten reverse stock split effected on September 8, 2025; all share data adjusted accordingly.
• ·Business Combination closing date: July 8, 2024.
• ·Company qualifies as emerging growth company and smaller reporting company with reduced disclosure requirements.
• ·Cash Holdback: 10% of net sales to B. Riley Principal Capital II until reaching Prior Transaction Cash Holdback Amount (one-third of $471,943 cash make-whole).
• ·Beneficial Ownership Limitation: 4.99% of outstanding shares.

03-03-2026

Limbach Holdings, Inc. reported record FY2025 revenue of $646.8M, up 24.7% YoY from $518.8M, with ODR revenue surging 40.6% to $485.7M (75.1% of total) and adjusted EBITDA rising 28.4% to $81.8M; Q4 revenue hit a record $186.9M (+30.1% YoY). However, GCR revenue declined 7.0% YoY to $161.1M for the year and 13.0% to $41.9M in Q4, total gross margin fell to 26.2% from 27.8%, and ODR gross margin dropped to 26.7% due to the Pioneer Power acquisition. The company announced a $50M share repurchase program and provided 2026 guidance of $730M-$760M revenue and $90M-$94M adjusted EBITDA.

• ·Q4 2025 gross margin declined to 25.7% from 30.3% YoY; ODR gross margin fell to 25.1% from 32.1% due to Pioneer Power integration.
• ·FY2025 total organic revenue growth was 3.6%; ODR organic growth 17.0%.
• ·2026 guidance: Revenue $730M-$760M, Adjusted EBITDA $90M-$94M, ODR organic growth 9-12%, gross margin 26-27%.
• ·Acquisitions contributed $109.1M to FY2025 revenue growth.
• ·Net cash from operations: Q4 $28.1M (vs $19.3M), FY $45.7M (vs $36.8M).

03-03-2026

SmartStop Self Storage REIT, Inc. disclosed same-store metrics for facilities stabilized since January 1, 2025 (excluding four properties), showing physical occupancy slightly down YoY to 92.1% as of December 31, 2025 (from 92.3%), up to 92.7% in January 2026 (from 92.1%), and flat at 92.7% in February 2026. However, monthly web rates declined YoY across all periods (e.g., -4.1% to $0.93 in Dec, -13.3% to $0.91 in Jan), as did move-in rates (e.g., -15% to $0.85 in Jan), while in-place rates were flat to slightly up (e.g., +0.6% to $1.65 in Feb). This provides a mixed operational picture with stable occupancy but softening new customer pricing.

• ·Same-store facilities defined as stabilized and comparable properties included in consolidated results since January 1, 2025.
• ·Disclosure furnished under Item 7.01, not deemed 'filed' for liability purposes.

03-03-2026

Leidos, Inc., a subsidiary of Leidos Holdings, Inc. (LDOS), issued $600M of 4.100% senior notes due 2029 and $800M of 5.000% senior notes due 2036, generating approximately $1,387M in net proceeds to fund a portion of the proposed acquisition of ENTRUST pursuant to the January 23, 2026 Stock Purchase Agreement. The notes are senior unsecured obligations guaranteed by Leidos Holdings, with interest payable semi-annually starting September 15, 2026, and include special mandatory redemption at 101% if the acquisition is not completed by August 14, 2026 or later extended date. The issuance is not conditioned on the acquisition closing.

• ·Notes issued under October 2020 Indenture supplemented by officers’ certificate dated March 2, 2026.
• ·Early redemption with make-whole premium before Feb 15, 2029 (2029 Notes) or Dec 15, 2035 (2036 Notes); par redemption thereafter.
• ·Change of control repurchase offer at 101% of principal.
• ·Acquisition Agreement dated January 23, 2026; End Date August 14, 2026.

03-03-2026

American Clean Resources Group, Inc. (ACRG) filed an 8-K on March 3, 2026, disclosing an event under Item 5.02 related to the departure of directors or certain officers, or election/appointment of directors or officers, effective March 2, 2026. No specific details on the individuals involved, reasons for departure, or any compensatory arrangements were provided in the filing metadata. No financial metrics, performance changes, or impacts were reported.

• ·Company CIK: 0000773717
• ·EIN: 840991764
• ·State of Incorporation: NV
• ·Fiscal Year End: December 31
• ·Business Address: 12567 West Cedar Drive, Suite 104, Lakewood, CO 80228-2039

03-03-2026

Atlantic Union Bankshares Corporation filed an 8-K on March 3, 2026, under Items 7.01 and 9.01, furnishing an updated investor handout (Exhibit 99.1) for use by management in meetings with investors, analysts, and other parties during Q1 2026. The handout is available on the company's Investor Relations website at https://investors.atlanticunionbank.com. No specific financial metrics or performance data were disclosed in the filing.

• ·Filing intended to satisfy Regulation FD Disclosure requirements.
• ·Securities registered on New York Stock Exchange: Common Stock (AUB) and Depositary Shares (AUB.PRA).

03-03-2026

On March 3, 2026, ONITY GROUP INC. (ONIT) filed an 8-K under Items 7.01 and 9.01, disclosing that Sean O’Neil, Executive Vice President and Chief Financial Officer, hosted an investor presentation at the J.P. Morgan 2026 Global Leveraged Finance Conference. The investor presentation materials are attached as Exhibit 99.1. This information is not deemed 'filed' under Section 18 of the Exchange Act.

• ·Filing registered under Florida jurisdiction, Commission File Number 1-13219, IRS Employer Identification No. 65-0039856.
• ·Principal executive offices: 1661 Worthington Road, Suite 100, West Palm Beach, Florida 33409.
• ·Common Stock ($0.01 Par Value) trades on NYSE under symbol ONIT.

03-03-2026

THOR Industries reported fiscal 2026 Q2 net sales of $2.13B, up 5.3% YoY, with YTD sales at $4.51B (+8.5% YoY), driven by strong North American Motorized segment growth (+29.3% sales, +28.3% units) and Adjusted EBITDA of $98.1M (+12.7% YoY). However, North American Towable sales declined 14.2% YoY with units down 23.0%, European gross margins fell 220 bps to 11.0% amid restructuring costs, and overall gross margin dipped 30 bps to 11.8%. Full-year FY26 guidance remains unchanged at $9.0-9.5B sales and $3.75-4.25 diluted EPS.

• ·North American Towable order backlog $621.5M as of Jan 31, 2026 (-42.1% YoY)
• ·North American Motorized order backlog $1.04B as of Jan 31, 2026 (-7.3% YoY)
• ·European order backlog $1.83B as of Jan 31, 2026 (+11.4% YoY)
• ·European restructuring costs $5.1M in Q2 FY26
• ·FY26 tax rate guidance 24-26% excluding discrete items

03-03-2026

Westinghouse Air Brake Technologies Corporation (Wabtec) filed an 8-K on March 3, 2026, disclosing under Regulation FD that it posted an investor presentation to its investor relations website, attached as Exhibit 99.1. The filing includes standard cautionary language on forward-looking statements referencing initiatives like Integration 3.0, portfolio optimization, and a 5-year outlook established in February 2025. No specific financial metrics, period comparisons, or performance data are provided in the filing itself.

• ·Investor presentation dated March 3, 2026, furnished as Exhibit 99.1 and not deemed 'filed' under Section 18 of the Exchange Act.
• ·5-year outlook originally established in February 2025.

03-03-2026

Chiron Real Estate LP (Issuer) and Chiron Real Estate Inc. (Parent), affiliates of Global Medical REIT Inc., entered into a Master Note and Guaranty Agreement dated March 2, 2026, with NYL Investors LLC and New York Life affiliates, establishing an uncommitted facility for issuing senior promissory notes in series with aggregate principal not exceeding the Available Facility Amount. Notes can be requested in minimum increments of $10M, with maturities and average lives up to 10 years, during an Issuance Period of up to three years. The facility provides flexible access to capital without current obligations or draws.

• ·Issuance Period extends until the earlier of the third anniversary of March 2, 2026, or other termination events.
• ·Individual Notes mature no more than 10 years from issuance date with average life no more than 10 years.
• ·Facility is explicitly uncommitted; New York Life has no obligation to purchase Notes or quote spreads.

03-03-2026

Wyndham Hotels & Resorts appointed Amit Sripathi as Chief Financial Officer effective immediately, succeeding interim CFO Kurt Albert, and named David Wilner as Chief Development Officer – North America, both reporting to President and CEO Geoff Ballotti. These leadership changes aim to drive FeePAR accretive net room growth and shareholder value, building on achievements like 20 consecutive quarters of organic net room growth. The company reaffirmed its full-year 2026 outlook originally provided in Q4 2025 earnings.

• ·Wyndham is the world’s largest hotel franchising company by number of franchised properties
• ·Filing date: March 03, 2026
• ·Sripathi joined Wyndham in 2021; Wilner has nearly 8 years at Wyndham and prior 20 years at La Quinta
• ·Outlook reaffirmed from Q4 2025 earnings released February 18, 2026

03-03-2026

Honeywell International Inc. announced on March 3, 2026, the filing of a Form 10 registration statement by its wholly owned subsidiary, Honeywell Aerospace Inc., with the SEC in connection with the anticipated spin-off of its Aerospace business into an independent, publicly traded company. A press release detailing the announcement is furnished as Exhibit 99.1. The filing includes extensive cautionary language on forward-looking statements, highlighting risks such as potential delays, failure to complete the Spin-Off, disruptions to operations, and uncertain financial impacts post-separation.

03-03-2026

Kontoor Brands reported Q4 2025 revenue of $1.02B, up 46% YoY driven by 36pp from Helly Hansen acquisition, though excluding HH and 53rd week it grew only 2%; full-year revenue reached $3.15B, up 21% YoY including 18pp from HH, with Wrangler up 6% but Lee down 5%. Adjusted EPS rose 26% to $1.73 in Q4 and 14% to $5.59 FY, with gross margins expanding; 2026 outlook projects revenue growth of 9% to $3.40-3.45B and adjusted EPS up 15-16% to $6.40-6.50, tempered by tariff increases. The company reduced inventory 26% QoQ to $567M, made a $200M debt payment, and repurchased $25M in shares.

• ·Lee international revenue decreased 6% YoY in Q4.
• ·Adjusted operating income ex Helly Hansen increased 9% YoY in Q4 to $110M.
• ·Pro-forma net leverage ratio at 2.0x end Q4.
• ·Quarterly dividend $0.53/share, payable March 20, 2026.
• ·$190M remaining under share repurchase authorization.
• ·2026 outlook assumes 15% tariff on new inventory receipts and 20% on pre-Feb 24 inventory.
• ·Cash from operations 2026 expected ~$425M; capex $45M.

03-03-2026

OPENLANE, Inc. announced an Investor Day event on March 3, 2026, beginning at 8:30 a.m. Eastern Time, as previously scheduled. The presentation slides used during the event are attached as Exhibit 99.1 and incorporated by reference under Item 7.01 Regulation FD Disclosure. The filing includes standard forward-looking statements disclaimers referencing risks in the Company's Form 10-K for the year ended December 31, 2025.

• ·Event held in connection with previously announced schedule
• ·Securities: Common Stock, par value $0.01 per share (OPLN on New York Stock Exchange)
• ·Principal executive offices: 11299 N. Illinois Street, Suite 500, Carmel, Indiana 46032

03-03-2026

Versant Media Group reported full-year 2025 revenue of $6.69B, down 5.3% YoY from $7.06B amid declines in linear distribution (-5.4%), advertising (-8.9%), and content licensing (-8.5%), while platforms grew 3.9%. Net income attributable to Versant dropped 31.8% to $930M and Adjusted EBITDA fell 14.5% to $2.42B from prior year levels. The company announced a $0.375 per share quarterly cash dividend (payable April 22, 2026) and a Board-approved $1B share repurchase authorization.

• ·Acquired Free TV Networks in January 2026 and INDY Cinema Group in Q4 2025.
• ·Net cash provided by operating activities $2.02B in 2025, down from $2.21B in 2024.
• ·Conference call scheduled for March 3, 2026, at 8:00 a.m. ET.

03-03-2026

Amylyx Pharmaceuticals reported Q4 and FY 2025 financial results, showing reduced R&D expenses of $21.2M (down 7% YoY) and $90.4M (down 13% YoY), SG&A expenses of $15.4M (down 10% YoY Q4) and $62.9M (down 45% YoY FY), and improved net losses of $33.0M (down 12% YoY Q4) and $144.7M (down 52% YoY FY), primarily due to lower spending on AMX0035 offset by avexitide development; however, product revenue was $0, down from $87.4M in FY2024. Cash position stood at $317M as of Dec 31, 2025, down from $344M at Q3 end but up from $177M at end-2024, providing runway into 2028. Pipeline progress includes completed recruitment for Phase 3 LUCIDITY trial of avexitide in PBH with topline data expected Q3 2026.

• ·Avexitide has FDA Breakthrough Therapy Designation for PBH and congenital HI, Orphan Drug Designation for hyperinsulinemic hypoglycemia.
• ·AMX0114 has FDA Fast Track Designation for ALS; Phase 1 LUMINA Cohort 1 (n=12) showed no treatment-related SAEs.
• ·IND-enabling studies for AMX0318 underway, targeting IND filing in 2027.
• ·Total assets $332.6M as of Dec 31, 2025 (up from $193.6M end-2024).

03-03-2026

AutoZone reported Q2 FY26 net sales of $4.3B, up 8.1% YoY, with domestic SSS up 3.4% and total company SSS up 3.3% on a constant currency basis, alongside opening 64 net new stores globally. However, gross margin declined 137 bps to 52.5% due to a LIFO charge, operating profit fell 1.2% to $698.5M, net income dropped to $468.9M from $487.9M, and diluted EPS decreased to $27.63 from $28.29. YTD net sales rose 8.2% to $8.9B, but operating profit declined 4.2% amid higher expenses.

• ·Net inventory per store: negative $105K (improved from negative $161K YoY)
• ·Operating expenses as % of sales: 36.1% vs 36.0% prior year
• ·Adjusted debt to EBITDAR: flat at 2.5x
• ·Expects to open 350-360 stores for full FY26
• ·Conference call: March 3, 2026 at 10:00 a.m. ET; replay through March 31, 2026

03-03-2026

Strata Critical Medical reported Q4 2025 revenue of $66.8 million, up 83.5% YoY to a record high, driven by 35.3% organic Logistics revenue growth to $49.2 million and $17.6 million from the new Clinical segment post-Keystone acquisition; full-year 2025 revenue hit $197.1 million (+34.3% YoY) with Adjusted EBITDA of $14.1 million, both beating guidance. However, full-year net loss from continuing operations widened 24.2% YoY to $20.1 million, Q4 operating loss increased 8.5% to $6.4 million, and Q4 operating cash flow was negative $8.3 million amid non-recurring items and working capital needs. The company raised FY2026 guidance to $260-275 million revenue and $29-33 million Adjusted EBITDA.

• ·Gross margin expanded 80bps YoY to 21.6% in Q4 2025 and 70bps to 20.9% FY2025.
• ·Closed $30M undrawn asset-backed credit facility with JP Morgan, expandable to $50M.
• ·Q4 2025 capital expenditures $2.0M primarily for aircraft maintenance and vehicles.
• ·Acquired one additional aircraft in early 2026 for new geographies.
• ·Keystone acquisition closed mid-September 2025.

03-03-2026

Brookfield Asset Management Ltd. (BAM) filed an 8-K on March 3, 2026, under Items 8.01 and 9.01, disclosing the issuance of a press release dated March 3, 2026 (Exhibit 99.1). The filing contains no specific financial or operational details from the press release. No performance metrics, positive or negative, are reported.

• ·Securities registered: Class A Limited Voting Shares (BAM) on New York Stock Exchange
• ·Commission File Number: 001-41563
• ·I.R.S. Employer Identification No.: 98-1702516

03-03-2026

ANI Pharmaceuticals, Inc. (ANIP) announced that President & CEO Nikhil Lalwani and members of the executive leadership team will present at the Raymond James & Associates’ 47th Annual Institutional Investors Conference in Orlando, Florida, on March 3, 2026. The company is providing an updated investor presentation (Exhibit 99.1) for use in meetings with investors and analysts. No specific financial metrics or performance data were disclosed in the filing.

• ·Presentation scheduled for March 3, 2026, at the Raymond James 47th Annual Institutional Investors Conference in Orlando, Florida.
• ·Investor presentation filed as Exhibit 99.1 under Item 9.01 and incorporated by reference under Item 7.01.

03-03-2026

Advantage Solutions Inc. reported Q4 2025 revenues of $932.1M, up 4.5% YoY, driven by strong 21.6% growth in Experiential Services, but full-year revenues declined 0.7% to $3.54B amid 10.9% drop in Branded Services. Adjusted EBITDA decreased 7.3% to $87.7M in Q4 and 6.8% to $331.8M for the year, reflecting declines across Branded (down 29.1% Q4) and Retailer Services (down 22.5% Q4), partially offset by Experiential's 114.8% Q4 surge. The company ended with $241M cash (up ~$40M sequentially), ~$55M from divestitures, and anticipates flat to low-single-digit revenue growth and flat to down mid-single-digit Adjusted EBITDA in 2026.

• ·Net Leverage Ratio: 4.4x as of Dec 31, 2025
• ·FY 2026 Outlook: Adjusted Unlevered Free Cash Flow $250-275M; Net Interest Expense $160-170M; Capex $50-60M
• ·Conference call: March 3, 2026, 8:30 am EDT

03-03-2026

Best Buy reported Q4 FY26 enterprise revenue of $13.8B, down 1% YoY with comparable sales declining 0.8% due to weakness in home theater and appliances, partially offset by gains in computing and mobile; domestic online comparable sales fell 2.3%. However, operating income margin expanded significantly to 5.2% from 1.6%, driving GAAP diluted EPS to $2.56 from $0.54, while full-year FY26 revenue grew 0.4% to $41.7B with comparable sales up 0.5% YoY and adjusted EPS slightly up to $6.43 from $6.37. The company raised its quarterly dividend 1% to $0.96 per share and issued FY27 guidance for revenue of $41.2B-$42.1B and adjusted EPS of $6.30-$6.60.

• ·Q4 FY26 domestic online sales as % of domestic revenue: 39.0% vs 39.5% prior year.
• ·International Q4 FY26 gross profit rate declined to 20.5% from 21.4%.
• ·Q4 FY26 share repurchases: $73M; FY26 total: $273M dividends + $801M repurchases.
• ·FY27 Q1 guidance: comparable sales ~1%, adjusted operating income rate ~3.9%.
• ·Quarterly dividend payable April 14, 2026 to shareholders of record March 24, 2026.
• ·Q4 FY26 cash and equivalents: $1.7B vs $1.6B prior year.

03-03-2026

Esperion Therapeutics (NASDAQ: ESPR) announced a definitive agreement to acquire Corstasis Therapeutics, adding Enbumyst™ (bumetanide nasal spray), the first FDA-approved nasal loop diuretic for edema in CHF, hepatic, and renal diseases, targeting a U.S. market exceeding $4B. The deal includes an upfront $75M cash payment, up to $180M in regulatory/commercial milestones, and low double-digit royalties on sales, expected to leverage Esperion’s cardiovascular infrastructure for double-digit revenue growth. Transaction closes in Q2 2026, subject to customary conditions, with no current financial declines noted but risks to consummation highlighted.

• ·FDA approval for Enbumyst: September 12, 2025
• ·Conference call: March 3, 2026 at 8:00 am ET
• ·Financed through existing credit facilities and Japanese royalties monetization
• ·Legal advisors: Gibson, Dunn & Crutcher LLP (Esperion), Arnold & Porter Kaye Scholer LLP (Corstasis)

03-03-2026

Netlist reported Q4 2025 net sales of $75.7M, up 79% QoQ and 121% YoY from $34.3M, with FY 2025 sales at $188.6M, up 28% YoY from $147.1M; gross profit surged to $6.9M in Q4 (up 2,620% YoY) and $11.4M FY (up 297% YoY). However, the company still posted a Q4 net loss of $2.2M (improved 82% YoY) and FY net loss of $24.8M (improved 54% YoY), alongside a working capital deficit of $6.4M and stockholders’ deficit of $5.2M as of Dec 27, 2025.

• ·Accounts payable decreased to $20.6M from $42.3M YoY.
• ·Deferred revenue increased to $30.6M from $0.04M YoY.
• ·Operating expenses declined to $36.95M FY 2025 from $58.11M FY 2024.
• ·Investor conference call scheduled for March 3, 2026 at 12:00 p.m. ET.

03-03-2026

GigaCloud Technology Inc's Audit Committee dismissed KPMG Huazhen LLP as its independent registered public accounting firm effective March 2, 2026, and appointed Grant Thornton LLP for the fiscal year ending December 31, 2026, primarily due to the mandatory five-year audit partner rotation requirement. KPMG's audit reports for fiscal years ended December 31, 2025 and 2024 contained no adverse opinions, qualifications, or modifications, and there were no disagreements or reportable events during those periods or the subsequent interim through March 2, 2026. The company issued a press release announcing the change on March 3, 2026.

• ·KPMG furnished a letter to the SEC dated March 3, 2026, agreeing with the company's statements (Exhibit 16.1).
• ·No prior consultations with Grant Thornton on accounting, auditing, or reporting matters during fiscal years 2024-2025 or interim period.

03-03-2026

Destiny Media Technologies Inc. held its Annual General Meeting on February 27, 2026, where stockholders elected five directors—Frederick Vandenberg, Hyonmyong Cho, S. Jay Graber, David Summers, and David Mossberg—with For votes ranging from 83% to 89% and minimal withholdings. Proposal Two to ratify Davidson and Company LLP as the independent registered public accounting firm for the fiscal year ending August 31, 2026, passed overwhelmingly with 99.5% For votes and negligible opposition.

• ·Annual General Meeting held on February 27, 2026
• ·Filing date: March 3, 2026
• ·Auditor ratification for fiscal year ending August 31, 2026
• ·Exact For votes for Hyonmyong Cho: 3,304,968; Withheld: 416,587
• ·Exact For votes for S. Jay Graber and David Summers: 3,328,348 each; Withheld: 393,207 each
• ·Exact For votes for David Mossberg: 3,304,968; Withheld: 416,587

03-03-2026

EVgo Inc. reported record Q4 2025 total revenue of $118M, up 75% YoY, and FY 2025 revenue of $384M, up 50% YoY, with charging network revenue hitting $64M in Q4 (+37% YoY) and $218M for the year (+40% YoY); network throughput grew 18% YoY to 99 GWh in Q4 and 32% to 366 GWh FY. The company achieved positive Adjusted EBITDA of $25M in Q4 and $12M FY, a milestone, but reported net losses of $11M Q4 (improved 69% YoY) and $95M FY (improved 25% YoY), alongside high GAAP capex of $49M Q4 (+108% YoY) and FY operating cash flow slightly negative at -$8M. 2026 guidance projects revenue of $410-470M but Adjusted EBITDA of -$20M to $20M, signaling potential flat or declining profitability.

• ·EVgo public network stalls: 3,890 as of Dec 31, 2025 (+13% YoY)
• ·EVgo dedicated network stalls: 140 (+27% YoY)
• ·EVgo eXtend™ stalls: 1,070 (+106% YoY)
• ·Q4 gross margin: 38.0% (+2,350 bps YoY); FY: 21.0% (+960 bps YoY)
• ·Autocharge+ accounted for 30% of Q4 charging sessions
• ·PlugShare: 7.8M registered users, 10.1M check-ins since inception
• ·2026 guidance: Total revenue $410M-$470M; Adjusted EBITDA -$20M to $20M

03-03-2026

CalciMedica reported a net loss of $29.6M for 2025, up from $13.7M in 2024, driven by $16.9M worse other income/expense including fair value adjustments and interest on a new promissory note, though R&D expenses rose modestly to $15.2M (+5%) and G&A fell to $7.9M (-19%). Cash position stood at $13.0M, sufficient into Q4 2026, amid clinical updates including no drug-related toxicity in the discontinued Phase 2 KOURAGE AKI trial and plans to finalize Auxora pivotal program design in AP during 1H 2026. CM5480 preclinical data in PAH was published, with IND anticipated in 2027.

• ·Phase 2 KOURAGE trial discontinued in Jan 2026 due to IDMC-recommended reevaluation of mortality imbalance, possibly from baseline disease severity; FDA discussions planned for Q2 2026.
• ·High-dose Auxora in CARPO trial: 100% reduction in new-onset severe respiratory failure (p<0.05), stratified win ratio 1.640 (p<0.05); no drug-related TESAEs or deaths.
• ·Total assets declined to $13.6M from $19.8M; stockholders' equity turned negative at -$6.6M from +$14.4M.

03-03-2026

908 Devices Inc. reported Q4 2025 revenue of $17.4M, up 21% YoY, and full-year 2025 revenue of $56.2M, up 18% YoY, with positive Adjusted EBITDA of $0.7M in Q4 but a full-year Adjusted EBITDA loss of $9.6M and net loss from continuing operations of $33.3M. Recurring revenue grew 22% YoY to $19.5M (35% of total), installed base expanded 24% to 3,736 devices, and cash position strengthened to $113.0M; however, GAAP gross margin remained flat at 51% for the full year. The company guides for 2026 revenue of $64.5M-$67.5M, implying 15-20% growth.

• ·OEM and funded partnership revenue: $1.0M in Q4 2025 (vs $0.7M Q4 2024); $3.0M FY 2025 (vs $1.6M FY 2024)
• ·Recurring revenue: 32% of Q4 2025 total revenue (vs 35% FY)
• ·Operating expenses Q4 2025: $6.1M (down from $23.4M Q4 2024 due to one-time items including goodwill impairment and contingent consideration changes)
• ·2026 revenue guidance: $64.5M to $67.5M

03-03-2026

On March 2, 2026, Trinseo PLC received NYSE notice to delist its ordinary shares (TS: NYSE) due to average market capitalization below the $15M continued listing standard over 30 trading days, resulting in immediate trading suspension. This follows December 12, 2025 notices for prior non-compliance with $50M market cap/equity thresholds and 30-day average share price below $1.00. Delisting via Form 25 will be effective 10 days post-filing, with potential OTC Pink trading but risks including Irish stamp duty at 1%, DTC ceasing settlements, and reduced liquidity.

• ·Trading in ordinary shares suspended immediately upon NYSE notice.
• ·Post-delisting transfers subject to Irish stamp duty at 1% unless exempt.
• ·DTC will cease clearing/settling trades and transfer positions to Computershare.
• ·No impact expected on business operations, partner/employee relationships, or SEC reporting.

03-03-2026

Antero Resources Corporation announced on March 3, 2026, its participation in the Raymond James & Associates’ 47th Annual Institutional Investors Conference. Presentation materials for the conference are available on the Company's website at www.anteroresources.com. The disclosure under Item 7.01 is not deemed 'filed' for liability purposes.

03-03-2026

On March 3, 2026, TXNM Energy, Inc. entered into a Distribution Agreement with sales agents BofA Securities, Inc., MUFG Securities Americas Inc., and Scotia Capital (USA) Inc., and forward purchasers Bank of America, N.A., MUFG Securities EMEA plc, and The Bank of Nova Scotia, enabling the potential sale of up to $125 million of its common stock through at-the-market offerings. The agreement also allows for forward stock purchase transactions, with no obligation to make any sales and commissions up to 2% of gross sales price per share. The company expects net proceeds from physical settlements of forward agreements but may elect cash or net share settlements, potentially receiving no proceeds or owing amounts.

• ·Sales may be made on NYSE, through market makers, electronic networks, or privately negotiated transactions including blocks.
• ·Forward Agreements allow Forward Purchasers to borrow and sell shares to hedge; Company receives no proceeds from borrowed share sales.
• ·Registration Statement on Form S-3ASR effective February 28, 2025, supplemented by prospectus dated March 3, 2026.
• ·Agreement terminable by Company or counterparties upon prior written notice.

03-03-2026

Scholar Rock reported Q4 and full year 2025 net losses widening to $91.0M ($0.88/share) and $377.9M ($3.29/share) from $66.5M ($0.61/share) and $246.3M ($2.47/share) in 2024, driven by sharp G&A increases to $45.0M (Q4) and $176.2M (full year) despite slight Q4 R&D decline, with no revenue recorded. Positively, cash stood at $367.6M as of Dec 31, 2025 bolstered by $60.4M warrant exercises, and a new $550M debt facility was secured from Blue Owl Capital to fund apitegromab commercialization. Pipeline advances include planned BLA resubmission and US launch in 2026 post-FDA reinspection of Catalent, EMA decision mid-2026, and Phase 2 initiations for FSHD and OPAL ongoing.

• ·Stock-based compensation Q4 2025: $19.4M (net loss), $5.3M (R&D), $14.1M (G&A); full year 2025: $75.6M (net loss), $20.7M (R&D), $54.9M (G&A)
• ·Debt facility matures February 2032
• ·No revenue recorded in any periods

03-03-2026

Passage BIO, Inc. filed a Form 8-K on 2026-03-03 disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This multi-item filing pertains to financial results with no specific revenue, earnings, or balance sheet metrics provided. No positive or negative performance indicators, guidance changes, or scheduled events were detailed.

03-03-2026

Roivant Sciences Ltd. announced via press release that the U.S. FDA has accepted the New Drug Application (NDA) for brepocitinib, filed by its subsidiary Priovant Therapeutics, for the treatment of dermatomyositis and granted Priority Review. This regulatory milestone advances the potential approval timeline for the drug. No financial or comparative performance data was disclosed.

• ·Filing date: March 3, 2026
• ·Press release date: March 3, 2026
• ·U.S. FDA granted Priority Review to the NDA

03-03-2026

Target Corporation (TGT) reported fourth-quarter 2025 net sales of $30.5B, down 1.5% YoY from $30.9B, with comparable sales declining 2.5% due to a 3.9% drop in store sales partially offset by 1.9% digital growth, though Food & Beverage, Beauty, Toys, Essentials, and Home categories grew and non-merchandise sales rose over 25%. Full-year 2025 net sales decreased 1.7% to $104.8B from $106.6B, GAAP EPS fell to $8.13 from $8.86, and Adjusted EPS was $7.57 in line with expectations despite declines in operating income. For 2026, guidance calls for ~2% net sales growth, operating margin up ~20 bps to 4.8%, and EPS of $7.50-$8.50.

• ·Q4 gross margin rate improved to 26.6% from 26.2% YoY due to lower shrink and supply chain costs.
• ·Full-year SG&A expense rate flat at 20.6% YoY on a GAAP basis, but Adjusted rose to 20.9%.
• ·Net interest expense increased to $445M full-year from $411M due to higher debt levels.
• ·Cash provided by operating activities $6.6B full-year, down from $7.4B.
• ·Inventory decreased to $12.3B from $12.7B as of Jan 31, 2026.

03-03-2026

L.B. Foster reported strong Q4 2025 results with net sales of $160.4M, up 25.1% YoY driven by 23.7% Rail and 27.3% Infrastructure growth, Adjusted EBITDA of $13.7M (+89.0% YoY), and operating cash flow of $22.2M used to reduce debt to $42.8M (leverage 1.0x). However, new orders fell 5.5% YoY, gross margins declined 260 bps to 19.7% due to UK Rail weakness and restructuring charges, and full-year 2025 sales grew only 1.7% to $540.0M with gross profit down 3.7%. The company issued 2026 guidance for net sales of $540-580M and Adjusted EBITDA of $41-46M.

03-03-2026

Saia, Inc. filed an 8-K on March 3, 2026, announcing the issuance of a press release with shipment and tonnage data for January and February 2026 under Item 8.01 Other Events. The press release is attached as Exhibit 99.1. No specific quantitative data from the press release is detailed in the filing body.

• ·Filing covers shipment and tonnage data specifically for January 2026 and February 2026
• ·Filed under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits)

03-03-2026

Ziff Davis, Inc. entered into a Securities Purchase Agreement on March 2, 2026, to sell its Connectivity division to Accenture Inc. for an aggregate purchase price of $1.2 billion in cash, subject to customary adjustments and regulatory approvals. The transaction closing is uncertain due to required approvals and other conditions, as highlighted in forward-looking statements noting risks such as economic downturns and regulatory hurdles. A press release was issued on March 3, 2026, with full details to be provided in a separate 8-K filing.

• ·Filing includes Exhibit 99.1: Press Release dated March 3, 2026.
• ·Separate Current Report on Form 8-K will provide additional information on the Purchase Agreement.
• ·Registrant details: Delaware incorporation, Commission File Number 0-25965, I.R.S. Employer Identification No. 47-1051457, principal offices at 360 Park Ave S., 17th Floor, New York, New York 10010.

03-03-2026

The Cigna Group announced David M. Cordani will retire as CEO effective July 1, 2026, transitioning to Executive Chair, with President and COO Brian Evanko succeeding him as CEO and joining the Board. Under Cordani's nearly 17-year tenure, the company grew from serving 46 million customers with $18B annual revenue to 180 million customer relationships and $275B revenue, delivering over 750% total shareholder return. The company reaffirmed its 2026 financial outlook with no changes indicated.

• ·Brian Evanko has nearly 30 years with the company.
• ·David M. Cordani has served nearly 17 years as CEO.
• ·Leadership transition period through July 1, 2026.

03-03-2026

MarketWise, Inc.'s Board of Directors declared a quarterly cash dividend of $0.25 per share and a special cash dividend of $0.20 per share for holders of Class A common stock on March 2, 2026. A comparable distribution of $0.25 per unit was approved for holders of MarketWise, LLC units. Both the dividend and distribution will be paid on March 31, 2026, to holders of record as of March 18, 2026.

• ·Filing submitted under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits) of Form 8-K

03-03-2026

Civeo reported Q4 2025 revenues of $161.6M, up 7% YoY from $151.0M, with Adjusted EBITDA rising 90% to $21.7M, driven by Australian growth (+9% revenues) and Canadian margin improvement (from -13% to 8%). However, full-year 2025 revenues declined 6% YoY to $638.8M from $682.1M amid Canadian occupancy pressures, resulting in a wider net loss of $20.1M versus $17.1M in 2024, despite Adjusted EBITDA growth to $88.2M (+10% YoY). The company repurchased 2.3M shares for $53.6M (17% of shares outstanding), nearing completion of its initial 20% repurchase authorization, and announced a new 10% authorization.

• ·Full year 2026 guidance: revenues $650M-$700M, Adjusted EBITDA $85M-$90M, capex $25M-$30M.
• ·Net leverage ratio of 1.9x as of Dec 31, 2025.
• ·Q4 2025 free cash flow $15.3M (vs $2.1M in Q4 2024).
• ·Conference call scheduled for March 3, 2026 at 11:00 a.m. ET.

03-03-2026

BioCardia, Inc. filed an 8-K on March 3, 2026, disclosing under Regulation FD a press release on late breaking echocardiography results from its Phase III CardiAMP HF Trial for ischemic heart failure with reduced ejection fraction (HFrEF). The results were presented by Dr. Amish Raval, M.D., National Co-Principal Investigator, in a late breaking clinical trial oral presentation session at the Technology and Heart Failure Therapeutics conference.

03-03-2026

Prime Medicine reported FY2025 financial results showing revenue growth of 55% YoY to $4.6M, driven by collaboration revenue, while R&D expenses increased 3.5% to $160.6M, G&A rose 4.3% to $52.3M, and net loss widened 3% YoY to $201.1M amid higher license costs and facility expenses offset by workforce reductions. Cash, cash equivalents, investments, and restricted cash totaled $191.4M as of Dec 31, 2025, down 6% from $204.5M prior year but providing runway into 2027. Pipeline progress includes planned IND/CTA for Wilson Disease in 1H2026 and AATD mid-2026, with initial data in 2027, and BLA submission for PM359 in CGD following FDA alignment.

• ·Total assets $342.7M as of Dec 31, 2025 (up from $297.5M YoY)
• ·Total liabilities $221.9M as of Dec 31, 2025 (up from $144.4M YoY)
• ·Collaboration revenue - related party $4.6M FY2025 (vs $1.6M FY2024)
• ·Net loss per share $(1.35) FY2025 (improved from $(1.65) FY2024)

03-03-2026

Pinterest announces a $1 billion strategic investment from Elliott Investment Management affiliates via convertible senior notes, with proceeds funding a $1 billion accelerated share repurchase (ASR) under a new $3.5 billion share repurchase program authorized by the Board. The company plans an additional $500 million in open-market repurchases via a 10b5-1 plan plus $473 million YTD under the prior program, totaling approximately $2 billion in near-term repurchases in H1 2026. Business highlights include record 2025 revenue, over 600 million MAU, and more than 80 billion monthly searches, with executives expressing confidence in undervalued shares and growth opportunities.

• ·Convertible notes: $1B principal, 1.75% annual interest, initial conversion price ~$22.72/share, mature March 1, 2031.
• ·ASR: $1B payment on March 5, 2026; expected completion by Q2 2026; final shares based on VWAP.
• ·Prior repurchase program authorized November 2024.

03-03-2026

Golden Matrix Group, Inc. (GMGI) filed an 8-K on March 3, 2026, covering Items 3.03 (Material Impairments), 5.03 (Charter/Bylaws Amendments), 8.01 (Other Events), and 9.01 (Exhibits), marked as a Material Event with a subcategory of Charter/Bylaws Amendments. The filing, sized at 1 MB, provides no detailed financial metrics, period-over-period comparisons, or specific outcomes on impairments or amendments in the available EDGAR listing. No improvements or declines are quantifiable from the provided data.

• ·CIK: 0001437925
• ·SIC: 7372 (SERVICES-PREPACKAGED SOFTWARE)
• ·Fiscal Year End: December 31
• ·Business Address: 3651 Lindell Road, Ste D131, Las Vegas, NV 89103
• ·Acc-no: 0001477932-26-001129

03-03-2026

Massimo Group (MAMO) appointed Crystal Mingqui Xu as Chief Financial Officer effective March 2, 2026, as announced on March 3, 2026. Ms. Xu, 46, brings over 23 years of experience in financial management, SEC reporting, and compliance from roles at Nasdaq-listed firms including Haoxi Health Technology Limited (HAO) and Ebang International Holdings Inc. (EBON). She will receive an annual base salary of $100,000, with eligibility for discretionary bonuses and company benefits.

• ·No family relationships between Ms. Xu and any director or executive officer.
• ·No related party transactions or arrangements requiring disclosure under Item 404(a) of Regulation S-K.
• ·Employment Agreement filed as Exhibit 10.1.

03-03-2026

On March 3, 2026, Canton Strategic Holdings, Inc. (Nasdaq: CNTN) issued a press release announcing the election of Mark Wendland to the Board of Directors of the Canton Foundation. The filing incorporates the press release as Exhibit 99.1 under Items 8.01 and 9.01. No financial metrics, performance changes, or other quantitative data were disclosed.

03-03-2026

Adial Pharmaceuticals entered into a collaboration framework agreement with Molteni Farmaceutici for a proposed exclusive partnership on AD04 commercialization in Europe, expecting an upfront payment, milestone payments, tiered royalties (high single digits to low double digits), and nearly $60M in total potential aggregate value from royalties and milestones upon execution of a definitive agreement. However, the Special Meeting of Shareholders on February 26, 2026, failed to convene due to lack of quorum, necessitating additional meetings every 90 days to seek approval for issuing up to 13,823,512 shares underlying New Warrants. This development advances AD04's European pathway but underscores challenges in obtaining timely stockholder approval.

• ·Molteni granted exclusivity period for due diligence and planning.
• ·New patent filing could extend Loss of Exclusivity (LOE) from 2031 to 2045.
• ·Genetic screening simplified from blood draw to cheek swab.
• ·Inducement Agreement dated November 25, 2025, requires meetings every 90 days until approval or warrants expire.

03-03-2026

Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) in-licensed a novel ctRNA biomarker assay from Cirna Diagnostics LLC for early diagnosis and surveillance of hepatocellular carcinoma (HCC) in high-risk cirrhosis patients, complementing its recently acquired mSEPT9 PCR-based assay as part of a strategic shift to liquid biopsy diagnostics. The ctRNA platform, validated across cohorts, offers earlier detection than DNA-based tests and potential expansion to other solid tumors. The global liquid biopsy market is valued at $10B, with the U.S. projected to reach nearly $9B by 2035, addressing current HCC surveillance that misses up to 75% of early-stage cancers.

• ·HCC represents 75-90% of liver cancer cases and is the sixth most common cancer worldwide, third deadliest globally.
• ·ctRNA assay detects mutant circulating tumor RNA for improved specificity in surveillance and early detection.

03-03-2026

Compass Diversified Holdings (CODI) elected Eugene Kim and Glenn Richter to its Board of Directors effective March 1, 2026, increasing the board size from seven to eight following Alexander S. Bhathal's resignation on February 28, 2026, due to other commitments. Kim, with over 25 years in private equity and investment banking, joins the Audit and Compensation Committees, while Richter, a former CFO of International Flavors & Fragrances Inc. and other major firms, joins the Audit and Nominating & Corporate Governance Committees. Company leadership expressed enthusiasm for their expertise in transactions, finance, operations, and transformations to support long-term value creation.

• ·Mr. Kim previously served as Managing Director at Compass Partners International and held roles at Goldman Sachs International and UBS/Warburg Dillon Read.
• ·Mr. Richter served as Senior Executive Vice President and CFO at TIAA, and CFO at RR Donnelley and Sears Roebuck & Co.
• ·Annual Report on Form 10-K for year ended December 31, 2025 filed with SEC on February 27, 2026.

03-03-2026

On March 2, 2026, Innventure, Inc. executives Michael Otworth and John Scott filed Form 4s disclosing the withholding of shares to cover tax obligations on vested RSUs settled on February 26, 2026. This non-discretionary transaction complied with Rule 16b-3 and award terms, with no open-market sales involved. Post-settlement, Otworth beneficially owns 3,274,030 shares and Scott owns 1,814,998 shares, indicating continued alignment with shareholders.

• ·Form 4 filings occurred on March 2, 2026, for RSU settlement on February 26, 2026.
• ·Withholding based on closing price of common stock on settlement date.
• ·Transaction exempt from Section 16(b).

03-03-2026

Oxford Square Capital Corp. reported Q4 2025 net asset value per share of $1.69, down from $1.95 QoQ and $2.30 YoY, driven by a $12.9M net decrease in net assets from operations including $16.0M unrealized depreciation and $2.3M realized losses. Net investment income was $5.4M ($0.07/share), slightly down QoQ from $5.6M despite total investment income rising to $10.4M from $10.2M, while expenses increased to $5.0M from $4.7M. The board declared monthly distributions of $0.035/share for April-June 2026.

• ·Weighted average credit rating 2.2 (fair value) and 2.3 (principal) as of Dec 31 2025, flat QoQ.
• ·Conference call held March 3, 2026 at 9:00 AM ET.
• ·Non-affiliated/non-control investments fair value $251.7M (Dec 2025) vs $256.2M (Dec 2024).

03-03-2026

PEDEVCO Corp. announced that its board of directors approved a 1-for-20 reverse stock split of its common stock. The reverse split is expected to become effective at 12:01 AM ET on March 13, 2026, with trading on a post-split basis beginning on the NYSE American at market open on the same day under the unchanged ticker 'PED' but with a new CUSIP number 70532Y402. No fractional shares will be issued; instead, holders will receive cash payments in lieu based on the closing price prior to the effective time.

• ·No change in trading symbol 'PED' post-split.
• ·Cash in lieu of fractional shares calculated as fraction multiplied by closing price on trading day before effective time.
• ·Information furnished under Item 7.01 is not 'filed' and not subject to liabilities under Section 18 of the Exchange Act.

03-03-2026

SRx Health Solutions, Inc. secured limited waivers and consents from certain existing investors under prior Note and Series A financings to enable a new securities purchase agreement for Series B Preferred Stock and related warrants. The waivers permit the new offering without triggering participation rights from the July 2025 Note Financing ($7.65M principal notes) and October 2025 Series A Financing ($15.23M proceeds). Series B Preferred will rank pari passu with Series A Preferred regarding dividends and liquidation preferences.

• ·Waivers executed by Existing Investors as Required Holders under Series A Purchase Agreement.
• ·Form of Waiver filed as Exhibit 10.1.

03-03-2026

Emergent BioSolutions Inc. (NYSE: EBS) announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026, with him serving on the Audit and Finance Committee. Mr. Fowler brings over three decades of leadership in healthcare and financial services, including senior roles at Wells Fargo Securities, Deutsche Bank, JPMorgan, and Salomon Brothers. The appointment aims to support the company's ongoing turnaround, transformation, and strategic priorities in global health preparedness.

• ·Mr. Fowler previously served as president of Large Scale Biology Corporation, founding partner of Bio-Strategic Directors, and managing partner of Baycrest Capital.
• ·Mr. Fowler earned a Juris Doctor from University of Virginia School of Law, MBA from University of Virginia Darden School of Business, and BA in History from University of Virginia.
• ·Company has been operating for over 25 years in public health protection.

03-03-2026

Atara Biotherapeutics, Inc. issued a press release on March 3, 2026, announcing that Pierre Fabre Pharmaceuticals, Inc. has submitted a request for a Type A meeting with the FDA to discuss plans addressing issues raised in the Complete Response Letter (CRL) for the EBVALLO™ Biologics License Application (BLA), issued on January 9, 2026. The update pertains to Tabelecleucel. The press release is filed as Exhibit 99.1.

• ·Form 8-K filed under Items 8.01 and 9.01.
• ·Registrant details: Delaware incorporation, CIK 0001604464, Nasdaq: ATRA.

03-03-2026

Sportsman’s Warehouse Holdings, Inc. reported preliminary FY2025 net sales of $1,209.2 million, up 1.0% YoY, with same-store sales also increasing 1.0% to $1,205.6 million, marking the first positive full-year SSS growth since 2020, alongside Adjusted EBITDA of $27.5 million. The balance sheet improved with ending inventory down $29.1 million or 8.5% to $312.9 million, net debt down 6.1% to $90.0 million, free cash flow of $7.6 million, and total liquidity of $107.8 million. However, the company identified approximately five underperforming stores for potential closure, contributing about -$1.5 million to FY2025 Adjusted EBITDA, and expects impairment charges related to leasehold improvements and operating lease assets.

• ·Q4 Adjusted EBITDA of approximately $9.6 million.
• ·Full FY2025 financial results to be reported on March 31, 2026.
• ·Preliminary results subject to change upon completion of year-end accounting and audit.

03-03-2026

MVB Financial Corp., holding company for MVB Bank Inc., redeemed all $40.0 million aggregate principal amount of its 4.25% Fixed-to-Floating Rate Subordinated Notes due 2030 on March 2, 2026, which qualified as Tier 2 capital and bore 7.67% interest at redemption. The redemption was funded by a $20.0 million draw on its revolving line of credit and cash on hand. No other period-over-period metrics or performance changes were reported.

• ·Redemption date: March 2, 2026; Filing date: March 3, 2026
• ·Notes structured to qualify as Tier 2 capital for regulatory purposes

03-03-2026

Safe Harbor reported 29% YoY growth in emerging US cannabis markets' average deposit balances over the 12 months ended February 4, 2026, now representing 31% of total average deposit balances, driven by over 100 new customer depository accounts and strategic entry into high-growth states. However, total average deposit balances grew more modestly at 4.5% YoY. The company has facilitated more than $26B in cannabis-related transactions across 41 states and territories.

• ·Emerging markets include: New Markets Coming Online (Delaware, Minnesota, Kentucky, Alabama, Mississippi); Licensing Expansion (New York, New Jersey, Maryland, Connecticut, Missouri, Ohio); Operator Footprint Expansion (Pennsylvania, Illinois, Virginia, Florida).
• ·Average deposit balances defined as trailing 14-day average daily deposit balances at financial institution partners.
• ·Emerging US markets defined as states with cannabis programs launched or materially expanded within the past five years.

03-03-2026

Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint (OHSA Composite Score), leading to the program's wind down, while YUPELRI net sales grew 12% YoY to $266.6M in FY2025 and 6% YoY to $70.6M in Q4 2025. The company holds $326.5M cash at Q4 2025 (no debt), expects ~$400M by end-Q1 2026 including recent milestones, and anticipates $60-70M annualized cash flow from Q3 2026 after 60% cost reductions (~$70M savings from 2025's ~$110M opex). The Strategic Review Committee is accelerating evaluation of alternatives, including a potential sale, to maximize shareholder value.

• ·Restructuring impacts ~50% of workforce, including full R&D wind down and 50% G&A cut, over next two quarters.
• ·YUPELRI co-promotion: 65% profit/loss to Viatris, 35% to Theravance.
• ·TRELEGY milestones from Royalty Pharma triggered by GSK global net sales thresholds.
• ·$2.6B Irish tax attributes.
• ·Preliminary financials subject to change in upcoming 10-K.

03-03-2026

Aphoenity International Holdings Inc. (formerly Luduson G Inc., ticker LDSN) changed its domicile from Delaware to Wyoming via statutory conversion on July 21, 2025, with continuity of assets, liabilities, and securities. Effective October 1, 2025, the company name changed to Aphoenity International Holdings Inc., and on November 18, 2025, it implemented a 1,000-for-1 reverse stock split (with fractional shares rounded up) and updated its EIN to 98-1872097, while maintaining par value at $0.0001 per share.

• ·Trading symbol: LDSN (OTC)
• ·CIK: 0001737193
• ·SIC: 7374 (Services-Computer Processing & Data Preparation)
• ·Principal address: 35/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong
• ·Phone: +852 2824 8560

03-03-2026

Upland Software reported Q4 2025 total revenue of $49.3M, down 28% YoY from $68.0M, and subscription revenue of $46.7M, down 27% YoY from $64.3M, primarily due to divestitures in Q1/Q2 2025. However, Adjusted EBITDA improved to $15.3M (31% margin) from $14.9M (22% margin), GAAP net income was $1.1M versus a $3.4M loss, and the company added 110 new customers including 15 major ones with 199 expansions. Guidance projects Q1 2026 revenue of $47.0-50.0M (24% decline at midpoint) and FY2026 revenue of $194.2-206.2M (8% decline at midpoint), offset by Adjusted EBITDA margin expansion to 28%.

• ·Earned 49 badges in G2’s Winter 2026 market reports.
• ·Recognized as a Major Player in IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 (November 2025).
• ·Included in Gartner Market Guide for RFP Response Management Applications (October 29, 2025).

03-03-2026

Jaguar Health, Inc. filed an 8-K announcing the board's approval of a Certificate of Designation for a new series of preferred stock, Series O Convertible Preferred Stock, with 4,475,074 authorized shares of preferred stock at $0.0001 par value. The certificate outlines terms including conversion rights, voting rights, and liquidation preferences. The document was executed on March 2, 2026, by CEO/President Lisa A. Conte and CFO Carol R. Lizak.

• ·Certificate governed by Delaware law; shares to be uncertificated.
• ·Requires majority holder approval for adverse amendments to Series O rights.
• ·Filed pursuant to Section 151 of Delaware General Corporation Law.

03-03-2026

Prairie Operating Co. (Nasdaq: PROP) announced leadership transitions, including the voluntary resignation of CEO and Chairman Edward Kovalik and the retirement of President and director Gary C. Hanna. The Board appointed director Richard N. Frommer as Interim President and CEO and Erik Thoresen as Chairman while initiating a search for a permanent CEO with a leading executive search firm. The changes are positioned as building on the company's operational foundation in the DJ Basin amid a search for permanent leadership.

• ·Richard N. Frommer served as director since November 2024; previously President and CEO of Great Western Petroleum (Feb 2013-Sep 2021) and SVP Rocky Mountain at Samson Resources (May 2002-Nov 2012).
• ·Erik Thoresen served as director since May 2023; partner at Boka Group since Nov 2022.
• ·Separation agreements entered with Edward Kovalik and Gary C. Hanna.

03-03-2026

Trex Company, Inc. entered into a Forward Share Repurchase Transaction Confirmation with Wells Fargo Bank on February 26, 2026, initiating a $100M accelerated share repurchase (ASR) program, with a prepayment made on February 27, 2026, and initial delivery of approximately 1.9M shares valued at 80% of the prepayment amount. The final share count will be based on the volume-weighted average price from February 27 to May 21, 2026, with potential for additional shares or cash/share return depending on the forward price. The prepayment was funded via borrowings under the company's line of credit, complying with Rules 10b5-1(c) and 10b-18.

• ·Calculation period: February 27, 2026 to May 21, 2026, subject to acceleration from April 9, 2026 or early termination.
• ·Initial shares valued at approximately 80% of prepayment based on February 26, 2026 closing price.
• ·ASR includes customary adjustments for market disruptions, hedging issues, or stock price thresholds.

03-03-2026

Nucor Corporation (NYSE: NUE) announced that Daniel R. Needham, Executive Vice President of Commercial, will retire effective June 20, 2026, after nearly 26 years with the company, having joined in 2000 and advanced through roles including Controller at multiple Nucor Steel facilities and General Manager positions before promotions to Vice President in 2016 and Executive Vice President in 2021. Chair and CEO Leon Topalian commended Needham's leadership, cultural commitment, and contributions to Nucor's position in the North American steel industry. No successor was named in the announcement.

• ·Filing date: March 3, 2026
• ·Nucor Executive Offices: 1915 Rexford Road, Charlotte, North Carolina 28211
• ·Investor/Analyst contacts: Chris Jacobi (chris.jacobi@nucor.com), Paul Donnelly (paul.donnelly@nucor.com)
• ·Media contact: Katherine Miller (katherine.miller@nucor.com)

03-03-2026

Trio Petroleum Corp filed Amendment No. 1 to its Prospectus Supplement on March 3, 2026, for its At Market Issuance Sales Agreement (ATM Agreement) with Ladenburg Thalmann & Co. Inc., originally entered on January 9, 2026, updating the aggregate Placement Shares eligible for sale to $3.292M after previously selling $3.6M worth (7.34M shares). The maximum aggregate offering amount under the ATM is now $6.89M. No financial performance metrics or period-over-period changes were reported.

• ·Registration Statement on Form S-3 (File No 333-281813) effective September 10, 2024.
• ·Legal opinion of Ellenoff Grossman & Schole LLP filed as Exhibit 5.1.
• ·ATM Agreement incorporated by reference from January 9, 2026 8-K (Exhibit 10.1).

03-03-2026

On March 3, 2026, Duke Energy, through its subsidiary Florida Progress, LLC, completed the first closing of an indirect minority investment by Peninsula Power Holdings L.P. (an affiliate of Brookfield Super-Core Infrastructure Partners), issuing 9.2% membership interests for approximately $2.8 billion. Future closings include additional investments of $200 million by December 31, 2026, $500 million by June 30, 2027, $1.5 billion by December 31, 2027, and $1 billion by June 30, 2028, increasing the investor's ownership to 19.7%. An Amended and Restated LLC Operating Agreement was entered, granting the investor two board seats out of eleven and certain governance protections.

• ·Investment Agreement originally dated August 4, 2025
• ·LLC Agreement includes investor protections such as approval rights for major decisions and put rights for membership interests (subject to minimum ownership thresholds)
• ·Transfer restrictions and rights apply to both Investor and Progress Energy

03-03-2026

Warner Music Group Corp. furnished a letter to stockholders on March 3, 2026, incorporated as Exhibit 99.1 under Regulation FD Disclosure. The company announced it will use online corporate communication channels, including the social media channel 'A Post From Robert Kyncl' at https://www.wmg.com/news, for ongoing direct communication with stockholders, which may include material non-public information. Investors are advised to monitor this channel alongside SEC filings, press releases, conference calls, and webcasts.

• ·Signed by Paul M. Robinson on March 3, 2026.
• ·Social media channel information deemed potentially material.

03-03-2026

The York Water Company reported 2025 annual operating revenues of $77.5M, up 3.4% YoY from $75.0M, driven by customer base growth and the Distribution System Improvement Charge (DSIC). However, net income declined 1.3% to $20.1M from $20.3M, with EPS down 2.1% to $1.39, due to higher operation and maintenance expenses, depreciation, interest costs, and lower AFUDC. In Q4 2025, revenues increased 3.2% to $19.5M, net income rose slightly by 0.5% to $5.2M, but EPS remained flat at $0.36.

• ·Invested $48.7M in 2025 capital projects including main extensions, enterprise software upgrade, infrastructure replacements.
• ·Anticipates $48M investments in 2026 and $2027 excluding acquisitions, for main extensions, software upgrade, water/wastewater plants, tanks, routine improvements.
• ·Dividends declared per common share $0.8856 for 2025, up from $0.8516 in 2024.

03-03-2026

Moog Inc. entered into the Eighth Amended and Restated Loan Agreement dated February 26, 2026, amending and restating the prior Seventh Amended and Restated Loan Agreement from May 30, 2025, with HSBC Bank USA, National Association as Administrative Agent and multiple lenders including Bank of America, JPMorgan Chase, and others. The agreement provides Aggregate Term Loan Commitments of $250M, along with revolving credit facilities, swingline loans, and letters of credit. No changes to commitment amounts or negative covenant impacts are specified in the filing.

• ·Guarantors secure obligations with liens on personal property assets.
• ·Previous agreements include Seventh (May 30, 2025), Sixth (October 27, 2022), Fifth (October 15, 2019), and earlier versions back to 1998.

03-03-2026

ConnectM Technology Solutions, Inc. announced via press release that its AI and technology subsidiary, Keen Labs, has extended the Hi-E™ line of energy storage systems for long duration applications to 10kWhr capacity. The updated line includes stackable solutions in addition to wall-mounted options, which can be configured by mixing and matching modules to meet exact energy requirements. No financial metrics, period-over-period comparisons, or performance declines were disclosed.

• ·Filing date: March 3, 2026
• ·Registrant is an emerging growth company

03-03-2026

Cullen/Frost Bankers, Inc. filed an 8-K/A on March 3, 2026, amending its February 11, 2026 8-K under Item 7.01 to replace the initial investor presentation with an updated version as of December 31, 2025. The revisions add information on the company's technology strategy, update peer data, and correct certain items from the original exhibit. No specific financial metrics or performance changes are disclosed in the filing.

• ·Presentation available at https://investor.frostbank.com
• ·References most recent 10-K filed February 5, 2026

03-03-2026

MainStreet Bancshares, Inc. announced on March 3, 2026, that it repurchased 174,280 shares of its common stock since the beginning of 2026 at an average price of $22.45 per share under its ongoing stock repurchase program, conducted in compliance with Rule 10b-18. This repurchase price was below the company's tangible book value of $25.52 per share as of December 31, 2025. The program does not obligate further repurchases and may be modified or terminated at any time.

• ·Repurchases conducted in accordance with Rule 10b-18 and other applicable legal requirements

03-03-2026

Packaging Corporation of America announced that Director Paul T. Stecko will retire from the Board and not stand for reelection at the 2026 Annual Meeting, reducing the Board size from 10 to 9 directors, with no disagreements on company matters. Fabian C. Strauss, age 45, was promoted to Senior Vice President – Finance, Controller & Treasurer effective March 1, 2026, with an annual base salary of $455,000, serving as principal accounting officer. The company also approved new forms of equity award agreements for LTI grants and entered a post-retirement agreement with former EVP and CFO Robert Mundy, vesting his outstanding equity awards including 9,928 RSUs.

• ·Paul T. Stecko's retirement not due to any disagreement with PCA on operations, policies, or practices.
• ·Fabian C. Strauss joined PCA in January 2022; previously Chief Accounting Officer at EOS Energy Storage, Inc. (Nov 2020-Jan 2022).
• ·No family relationships or reportable transactions under Item 404(a) for Mr. Strauss.
• ·New equity agreements include revised vesting for retirement (age 55 + service = 70), death, or disability.
• ·Robert Mundy's retirement as Special Advisor effective March 1, 2026; subject to confidentiality, non-compete, non-solicit covenants.

03-03-2026

PDS Biotechnology Corporation received a Nasdaq deficiency notice on February 25, 2026, stating that its common stock (PDSB) closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The Company has 180 calendar days until August 24, 2026, to regain compliance by achieving a $1.00 closing price for 10 consecutive business days, with no immediate impact on trading. While it may pursue options like a reverse stock split and could qualify for a second 180-day period, there is no assurance of compliance, risking delisting.

• ·Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement)
• ·Eligibility for second 180-day period requires meeting market value of publicly held shares and other initial listing standards
• ·Company headquartered at 303A College Road East, Princeton, NJ 08540

03-03-2026

Network-1 Technologies, Inc. (NYSE American: NTIP) declared a semi-annual cash dividend of $0.05 per common share on February 27, 2026, payable on March 30, 2026 to stockholders of record as of March 16, 2026, pursuant to its dividend policy. The policy is subject to periodic review and potential change based on cash position, financial requirements, earnings, and other factors. The company owns 119 U.S. patents and 17 international patents, including portfolios in M2M/IoT, HFT, Cox, and Smart Home, with historical licensing revenues of over $188M from its Remote Power Patent and $47.15M from its Mirror Worlds Patent Portfolio through September 30, 2025.

• ·Network-1 is engaged in development, licensing, and protection of intellectual property, focusing on acquiring high-quality patents for licensing opportunities.

03-03-2026

Xcel Energy Inc. announced via 8-K the execution of Supplemental Indenture No. 2 dated March 3, 2026, issuing $800M aggregate principal amount of 5.75% Fixed-to-Fixed Reset Rate Junior Subordinated Notes, Series due 2056, with U.S. Bank Trust Company, National Association as trustee. The filing includes exhibits such as the indenture and legal opinions from Jones Day. No financial performance metrics or period-over-period comparisons were reported.

• ·Filing Items: 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits)
• ·Exhibits include: 4.01 (Supplemental Indenture), 5.01 (Opinion of Jones Day), 8.01 (Tax Opinion of Jones Day), 104 (Inline XBRL)

03-03-2026

GATX Corp filed an 8-K/A on March 03, 2026, under Items 2.01 (Completion of Acquisition or Disposition of Assets) and 9.01 (Financial Statements and Exhibits), amending prior disclosure on a transaction completion. The filing attaches Exhibit 99.1 referencing a 'railcarvexout12312' document, likely detailing a railcar asset carve-out or related disposition. No financial metrics or performance data were disclosed in the provided content.

• ·Filing Type: 8-K/A
• ·Items Reported: 2.01, 9.01
• ·Subcategory: Acquisition/Disposition Completion
• ·Exhibit: EX-99.1 (ex-991railcarvexout12312.htm)

03-03-2026

On March 2, 2026, Mac Accounting Group & CPAs, LLP resigned as IMA Tech's independent registered public accounting firm effective immediately, after serving for fiscal years ended April 30, 2025 and 2024, and the interim period ended October 31, 2025. The Company appointed Boladale Lawal & Co. as the new independent auditor on the same date, effective immediately. There were no disagreements on accounting principles, financial disclosures, auditing scope, or reportable events during the relevant periods.

• ·Mac Accounting Group reviewed the quarterly report for the period ended October 31, 2025.
• ·The Company authorized Mac Accounting Group to respond fully to inquiries from Boladale Lawal & Co.
• ·Letter from Mac Accounting Group to SEC attached as Exhibit 16.1, dated March 3, 2025.

03-03-2026

In ongoing receivership proceedings for Global Tech Industries Group, Inc. appointed on September 18, 2024, the court-approved receiver Paul L. Strickland finalized a confidential settlement agreement with former President and Director Kathy Griffin and family members on December 22, 2025, with court approval on February 26, 2026. Separately, the Company's wholly-owned subsidiary TTII Strategic Acquisitions & Equity Group Inc. obtained a default judgment against Astra Energy, Inc. on March 2, 2026, following a complaint filed on July 22, 2025. These legal resolutions address prior disputes but occur under court-supervised receivership, with no financial details disclosed.

• ·Receivership case: White Rocks (BVI) Holdings Inc., et al., v. Reichman, et al., Case No.: A-24-896359-B, Clark County, Nevada District Court
• ·Exhibits include Order 99.1 approving Griffin settlement and 99.2 for ASRE judgment

03-03-2026

TLGY Acquisition Corp. and StablecoinX Inc. continue progressing toward their business combination announced on July 21, 2025, with the Registration Statement on Form S-4 declared effective on February 17, 2026, and definitive proxy statement/prospectus mailed to TLGY shareholders as of February 4, 2026, for an upcoming Extraordinary General Meeting. SC Assets posted updates on X.com and LinkedIn regarding the proposed Transaction on March 3, 2026. However, the filing emphasizes significant risks including potential failure to complete the Transaction timely or at all, high redemptions by public shareholders, ENA price volatility, regulatory delays, and operational challenges post-merger.

• ·Registration Statement (Form S-4) declared effective on February 17, 2026.
• ·TLGY shareholders record date: February 4, 2026.
• ·TLGY Annual Report on Form 10-K for fiscal year ended December 31, 2024, filed March 5, 2025.

03-03-2026

Alignment Healthcare, Inc. filed a 424B7 prospectus supplement for a selling stockholder to offer 13,167,733 shares of common stock at $19.460 per share, totaling $256.2M in gross proceeds, with net proceeds to the seller of $255.4M after $0.9M underwriting discount. The company is not selling shares and will receive no proceeds. Post-offering shares outstanding will be 204.3M based on February 23, 2026 figures.

• ·Delivery of shares expected on March 4, 2026 in New York, NY.
• ·Operations primarily in California, North Carolina, Nevada, Arizona, and Texas.
• ·Principal executive office: 1100 W. Town and Country Road, Suite 1600, Orange, California 92868.

03-03-2026

APEX Tech Acquisition Inc., a Cayman Islands-incorporated blank check company (SPAC), priced its initial public offering of 10,000,000 units at $10.00 per unit, raising $100M, announced on February 25, 2026. Units are set to trade on NYSE under 'TRADU' starting February 26, 2026, with closing expected February 27, 2026, subject to conditions. Underwriters, led by A.G.P./Alliance Global Partners, have a 45-day option to purchase up to 1,500,000 additional units for over-allotments.

• ·IPO registration statement (Form S-1, File No. 333-291936) declared effective February 25, 2026
• ·45-day underwriter option to cover over-allotments
• ·Company targeting merger, share exchange, asset acquisition, or similar business combination with unspecified industries

03-03-2026

Amicus Therapeutics, Inc. shareholders overwhelmingly approved the merger with BioMarin Pharmaceutical Inc. at a special meeting on March 3, 2026, with 234.6M votes for (99.95% of votes cast) versus minimal opposition of 119K votes against, out of 313.9M eligible shares and 74.79% attendance. The advisory compensation proposal also passed with 209.2M votes for (89.1% of votes cast). While stockholder approval is secured, the transaction remains subject to remaining regulatory clearances from European and Japanese authorities, with closure expected in Q2 2026.

• ·Record date for special meeting: January 28, 2026.
• ·Definitive proxy statement filed with SEC: February 2, 2026.
• ·U.S. Federal Trade Commission granted early termination of HSR waiting period: February 11, 2026.
• ·Adjournment proposal not voted on due to sufficient Merger Proposal support.
• ·No broker non-votes for either proposal.

03-03-2026

Global Arena Holding, Inc. (Parent) and its wholly-owned subsidiary Global Election Services, Inc. (GE Services) entered into an Asset Purchase Agreement dated February 26, 2026, with GES Acquisition Corp. and Easterly CV VI LLC, to sell substantially all assets of their technology-enabled election services business (including fixed assets, contracts, IP, receivables, and goodwill), excluding cash and certain other items. Consideration consists of $2.4M cash payable to GE Services and 2,571,428 shares of GES Acquisition common stock issued to Parent, with GES Acquisition assuming only specified post-closing liabilities. No financial performance metrics or period-over-period comparisons are provided in the agreement.

• ·Assets exclude cash, cash equivalents, tax returns, insurance policies, and non-assumed contracts.
• ·Assumed Liabilities limited to post-Effective Time obligations under Assumed Contracts, IP, and Permits.
• ·Exhibits include Certificate of Designations for Series A Convertible Preferred Stock, Promissory Note, Employment Agreements, NDA/IP Rights Agreement, and Bill of Sale.

03-03-2026

Plains All American Pipeline, L.P. executed the Third Amendment to its Credit Agreement on February 26, 2026, replacing Plains Midstream Canada ULC (PMCULC) as a borrower with Plains Canada Liquid Pipelines ULC (PCLPULC), while releasing PMCULC from all obligations under the loan documents after full repayment of its outstanding loans. PCLPULC assumes borrower status with obligations guaranteed by the Company, and the amendment updates all references in the original agreement dated August 20, 2021. No changes to commitment amounts or other financial terms are specified.

• ·Original Credit Agreement dated August 20, 2021; First Amendment dated August 22, 2022; Second Amendment dated August 19, 2024.
• ·Conditions for effectiveness include executed counterparts, corporate certificates, legal opinions, KYC compliance, and full repayment of PMCULC obligations.

03-03-2026

Weyco Group reported Q4 2025 net sales of $76.8M, down 5% YoY from $80.5M, and full-year sales of $276.2M, down 5% from $290.3M, with gross margins contracting to 44.1% and 43.2% respectively due to $16M in incremental tariffs. While Florsheim wholesale sales hit a record $92.0M (up 2% YoY), other brands like Nunn Bush (-13% Q4), Stacy Adams (-13% Q4), and BOGS (-6% Q4, -11% FY) declined amid soft demand and retail uncertainty. Operating earnings fell 12% to $10.2M in Q4 and 20% to $29.2M for the year, though cash rose to $96M from $71M.

• ·Quarterly dividend declared $0.27 per share, record date March 13, 2026, payable March 31, 2026.
• ·FY 2025 diluted EPS $2.41, down from $3.16.
• ·Inventories decreased to $65.9M from $74.0M YoY.
• ·Conference call scheduled March 4, 2026 at 11:00 a.m. ET.
• ·U.S. Supreme Court ruled Feb 20, 2026 invalidating IEEPA tariffs; company filed lawsuit in Dec 2025 for refunds.

03-03-2026

Intel Corporation announced that Frank Yeary, Chair of the Board, intends to retire effective upon the conclusion of the 2026 Annual Meeting of Stockholders, with the Board size reducing from 12 to 11 directors. Dr. Craig H. Barratt was named as the new Chair effective the same date. The announcement was made via a press release dated March 3, 2026, following Yeary's notification to the Board on February 27, 2026.

• ·Filing date: March 3, 2026
• ·Date of earliest event reported: February 27, 2026
• ·Press release titled: 'Intel Board Chair Frank D. Yeary to Retire Following Annual Meeting; Dr. Craig H. Barratt Elected as Chair'

03-03-2026

Arcturus Therapeutics reported Q4 and FY 2025 financial results with revenue declining sharply to $7.2M (-68%) and $82.0M (-46%) YoY, respectively, due to lower CSL collaboration activity, though operating expenses fell more significantly to $38.5M (-31%) and $158.3M (-36%) YoY, narrowing net losses to $29.1M and $65.8M. Cash position stood at $232.8M, extending runway into Q2 2028 amid disciplined cost management. Pipeline progressed positively with ARCT-032 cleared for 12-week Phase 2 study in H1 2026 and ARCT-810 regulatory meetings on track for H1 2026, but R&D expenses remained elevated at $112.2M for FY despite YoY decline.

• ·Lawsuit against AbbVie Inc. and Capstan Therapeutics, Inc. filed September 23, 2025, remains ongoing.
• ·UK MHRA granted approval for KOSTAIVE® in January 2026 for individuals aged 18+.
• ·Investor conference call held March 3, 2026 at 4:30 p.m. ET.

03-03-2026

CrowdStrike reported Q4 FY26 total revenue of $1.31B, up 23% YoY from $1.06B, and ending ARR of $5.25B, up 24% YoY with record net new ARR of $331M (+47% YoY); full year revenue grew 22% YoY to $4.81B with record non-GAAP net income of $957M and free cash flow of $1.24B. However, full year GAAP operating loss widened to $293M from $116M prior year, and GAAP net loss increased to $163M from $15M. The company announced acquisitions of SGNL and Seraphic Security, repurchased $51M in shares, and raised FY27 ARR guidance to $6.47B-$6.52B.

• ·Subscription gross margin GAAP 79% Q4 FY26 (up from 77% YoY), non-GAAP 81% (up from 80%).
• ·Q4 GAAP net income $38.7M vs loss of $86.3M YoY; non-GAAP net income $289.1M (up from $205.3M).
• ·FY27 guidance: Q1 ARR $5.50B-$5.50B, total rev $1.36B-$1.36B; FY ARR $6.47B-$6.52B.
• ·100% detection and protection in 2025 MITRE ATT&CK Evaluations.
• ·Forrester TEI study: 273% ROI for customers replacing legacy endpoint security.
• ·New regional cloud deployments planned for Saudi Arabia, India, UAE.

03-03-2026

PennantPark Investment Corporation (PNNT) filed an 8-K on March 3, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing its monthly distribution via a press release furnished as Exhibit 99.1. No specific details on the distribution amount or performance metrics were provided in the filing. The announcement is not deemed 'filed' and includes standard forward-looking statement disclaimers.

• ·Common Stock, par value $0.001 per share, traded as PNNT on the New York Stock Exchange.
• ·Principal executive offices: 1691 Michigan Avenue, Miami Beach, Florida 33139.

03-03-2026

TransCode Therapeutics, Inc. designated 1,214,204 shares of Series C Non-Voting Convertible Preferred Stock with a par value of $0.0001 per share, approved by the Board on February 27, 2026, as part of an Equity Issuance and Registration Rights Agreement with Unleash Immuno Oncolytics, Inc. dated March 2, 2026. The Series C shares are convertible 1:1 into Common Stock following stockholder approval per Nasdaq rules, with no general voting rights but protective provisions, and rank pari passu with Common Stock and Series A/B Preferred in liquidation. No dividends beyond those on Common Stock (as-if-converted), and includes a beneficial ownership limitation to prevent excessive ownership.

• ·Conversion effective after 5:00 p.m. ET on third Business Day post-stockholder approval.
• ·Holders entitled to same dividends as Common Stock on as-if-converted basis (excluding CVR Agreement rights).
• ·Beneficial Ownership Limitation prevents conversion if Holder would exceed calculated ownership threshold per Section 13(d).
• ·Liquidation treated pari passu with Common and Series A/B Non-Voting Preferred Stock.

03-03-2026

On March 3, 2026, BARK, Inc. filed an 8-K announcing that Matt Meeker, its Chief Executive Officer and Executive Chair of the Board, voluntarily withdrew from participation as a member in Great Dane Ventures, LLC. The announcement was made via a press release attached as Exhibit 99.1. No financial impacts or further details on implications were disclosed.

03-03-2026

VSEE Health, Inc. held a special stockholder meeting on March 2, 2026, achieving quorum with 50.46% participation (21,824,877 votes out of 43,400,255 entitled). Stockholders approved Proposal 1, authorizing issuance of up to 19,672,130 common shares upon warrant exercise per Nasdaq Rule 5635(d), with 14,109,726 FOR and 7,698,963 AGAINST votes. Proposal 2 to adjourn the meeting was approved (18,629,017 FOR) but withdrawn as unnecessary.

• ·Record date for Special Meeting: February 2, 2026
• ·Proxy statement filed February 5, 2026, supplemented February 17, 2026
• ·Total votes entitled: 43,244,355 (common) + 155,900 (preferred) = 43,400,255

03-03-2026

On February 27, 2026, the Boards of Northpointe Bancshares, Inc. and its subsidiary Northpointe Bank received notices from directors R. Jeffrey Dean, Bruce L. Edger, and John M. Eggemeyer III of their intention to retire at the end of their current terms, expiring at the 2026 Annual Meeting of Stockholders, and they will not stand for reelection. Their decisions are not due to any disagreements with the Company on operations, policies, or practices. The Company expressed appreciation for their service, with Mr. Dean serving since 1999, Mr. Edger since 2005, and Mr. Eggemeyer since 2019.

• ·Mr. Dean serves on Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee.
• ·Mr. Edger serves on Compensation Committee and Corporate Governance and Nominating Committee.
• ·Mr. Eggemeyer serves on Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee.
• ·Directors will continue service through the 2026 Annual Meeting of Stockholders.

03-03-2026

PennantPark Floating Rate Capital Ltd. filed an 8-K on March 3, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing its monthly distribution via a press release furnished as Exhibit 99.1. The filing includes standard forward-looking statement disclaimers and confirms the information is furnished, not filed. No specific financial metrics or distribution amounts were detailed in the Form 8-K itself.

• ·Common Stock (par value $0.001 per share) trades under symbol PFLT on the New York Stock Exchange.
• ·Principal executive offices: 1691 Michigan Avenue, Miami Beach, Florida 33139; Telephone: (786) 297-9500.

03-03-2026

B&G Foods reported Q4 2025 net sales of $539.6M, down 2.2% YoY due to divestitures, though base business net sales rose 0.8% on pricing and volume gains; full-year 2025 net sales fell 5.4% to $1.83B with base business down 4.0% on volume declines. Adjusted EBITDA declined 1.6% to $84.7M in Q4 and 7.9% to $272.2M for the year, while segments showed mixed results with Meals up 13.3% in Q4 adjusted EBITDA but Specialty and Frozen & Vegetables declining. FY2026 guidance projects net sales of $1.655B-$1.695B and adjusted EBITDA of $265M-$275M amid ongoing divestitures of non-core brands like Green Giant U.S.

• ·Q4 gross profit margin improved to 22.7% from 21.5% YoY; adjusted gross profit margin to 23.0% from 22.2%.
• ·SG&A expenses rose 7.3% to $54.0M in Q4 and 3.7% to $194.9M for FY.
• ·Net interest expense down 2.1% to $38.8M in Q4 and 5.0% to $149.6M for FY.
• ·Non-cash impairments: $35.5M in Q4 FY25 (vs. $320M in Q4 FY24).
• ·Divested brands net sales in Q4 FY24: Le Sueur U.S. $12.4M, Don Pepino/Sclafani $4.0M.

03-03-2026

Immunome reported full-year 2025 financial results with a net loss of $212.4M, improved 27% YoY from $293.0M in 2024 due to sharply lower in-process R&D expenses ($10.0M vs. $152.3M), though R&D expenses rose 37% to $177.3M and G&A increased 33% to $43.8M, while collaboration revenue declined 23% to $6.9M. Cash and equivalents reached $653.5M as of December 31, 2025, bolstered by $460.5M gross proceeds from a December 2025 public offering (net $432.4M), extending runway into 2028. Positive Phase 3 RINGSIDE topline results for varegacestat showed an 84% reduction in progression risk (HR=0.16), ORR of 56% vs. 9% placebo, supporting a planned 2Q 2026 NDA submission, with ADC pipeline advancements ongoing.

• ·Share-based compensation: $25.7M in 2025 (R&D $11.2M, G&A $14.5M) vs. $15.7M in 2024.
• ·Net loss per share: $(2.43) in 2025 vs. $(5.00) in 2024.
• ·Total current assets: $660.8M as of Dec 31, 2025 vs. $221.3M as of Dec 31, 2024.

03-03-2026

China Pharma Holdings, Inc.'s (CPHI) wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), entered into a Technology Transfer Agreement on February 26, 2026, acquiring the Invention Patent for Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation (Patent No. 2018102273158) from Xiaoyan Zhang for $6.93M, payable in 12,600,000 restricted common shares at $0.55 per share. The agreement also includes technical services for product R&D, registration materials, and applications. Shares are issued under Regulation S exemption to a non-U.S. person.

• ·Patent No. 2018102273158, granted March 19, 2018, valid until March 19, 2038.
• ·Technical services include product R&D, registration materials preparation, and application filing.
• ·Issued under Regulation S exemption for offshore transaction to non-U.S. person.

03-03-2026

On March 3, 2026, Smart Sand, Inc. entered into a Rule 10b5-1 trading plan to support its share repurchase program, authorizing purchases of up to $2.5 million in common stock (including commissions). The plan permits repurchases starting no earlier than March 16, 2026, and ending by the earlier of full utilization or May 11, 2026, in compliance with Rule 10b-18 volume limits. This structured approach allows repurchases during potential blackout periods, signaling management confidence in the stock.

• ·Trading plan references Company's 2025 Annual Report on Form 10-K and Form 8-K, both filed February 27, 2026.
• ·Repurchases limited to maximum daily target volume under Rule 10b-18.
• ·Broker has authority to execute trades on Company's behalf; no obligation to purchase specific shares or at specific times.

03-03-2026

MIRA Pharmaceuticals completed dosing in its Phase 1 clinical trial of Ketamir-2, a proprietary selective oral NMDA receptor modulator, in 56 healthy volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, reporting no serious adverse events, dose-limiting toxicities, or clinically significant dissociative effects. The study, conducted at Hadassah Medical Center, evaluated SAD from 50 mg to 600 mg (32 participants) and MAD of 150 mg, 300 mg, or 600 mg daily for five days (24 participants). The company plans to submit for a Phase 2a proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN) patients to the FDA in the first half of 2026.

• ·Study conducted at the Clinical Pharmacology Unit of Hadassah Medical Center in Jerusalem, Israel.
• ·Database lock, unblinding, and final pharmacokinetic/safety analyses underway.
• ·Plans to present Phase 1 data at an upcoming scientific meeting.
• ·No FDA-approved therapies specifically for CIPN; current management uses off-label agents or IV ketamine.

03-03-2026

Ross Stores reported fourth quarter FY25 sales of $6.6B, up 12% YoY from $5.9B with comparable store sales rising a robust 9%, and diluted EPS of $2.00 exceeding guidance and prior-year $1.79 (21% growth excluding prior gain). Full-year FY25 sales reached a record $22.8B, up 8% YoY, with comparable sales +5%, but net income was flat at approximately $2.1B and diluted EPS growth was modest at 4.6% to $6.61 (10% excluding items). The company announced a new $2.55B two-year stock repurchase authorization (21% increase) and a 10% quarterly dividend hike to $0.445 per share, alongside FY26 guidance of 3-4% comparable sales growth and EPS of $7.02-$7.36.

• ·Q1 FY26 guidance: comparable sales +7% to +8%, EPS $1.60 to $1.67 (vs. prior $1.47)
• ·FY26 guidance: comparable sales +3% to +4%, EPS $7.02 to $7.36 (vs. FY25 $6.61)
• ·Quarterly dividend payable March 31, 2026 to shareholders of record March 13, 2026
• ·Cash from operations FY25 $3.0B, up from $2.4B prior year
• ·Capital expenditures FY25 $819M

03-03-2026

Selling stockholders, including KKR Phoenix Aggregator L.P. and certain management members, are offering 20,000,000 shares of BrightSpring Health Services, Inc. common stock at $41.15 per share, for total gross proceeds of approximately $823M; the company will not receive proceeds except from any cash exercises of stock options by management sellers. Concurrently, subject to offering completion, the company intends to repurchase 1,464,807 shares from the underwriter at $40.961 per share, with no underwriting discount on those shares and the repurchase not conditioning the offering. On March 2, 2026, the stock closed at $41.58 per share on Nasdaq.

• ·Prospectus supplement dated March 2, 2026; expected share delivery on or about March 4, 2026.
• ·Nasdaq symbol: BTSG; closing price March 2, 2026: $41.58 per share.

03-03-2026

FS Specialty Lending Fund filed an 8-K on March 3, 2026, announcing under Item 7.01 that a presentation containing financial and operating information will be made available in the Investor Relations section of its website (https://www.fssl.futurestandard.com/) after market close on March 3, 2026. The filing includes standard forward-looking statements disclaimers but discloses no specific financial metrics, amounts, or performance data. No period-over-period comparisons or quantitative details are provided in the document itself.

• ·Commission File Number: 811-24080
• ·I.R.S. Employer Identification No.: 33-4638504
• ·Principal executive offices: 3025 JFK Boulevard, OFC 500, Philadelphia, Pennsylvania 19104

03-03-2026

Crexendo reported fiscal year 2025 revenue of $68.2 million, up 12% YoY from $60.8 million, driven by strong 27% growth in software solutions revenue to $29.7 million, though product revenue declined 16% to $4.7 million and service revenue grew modestly 6% to $33.8 million. Net income improved to $5.1 million from $1.7 million in FY2024, with Q4 revenue up 11% to $18.1 million but product revenue down 6% to $1.1 million. The company ended the year with $31.4 million in cash and cash equivalents, up from $18.2 million, and highlighted 10 consecutive GAAP profitable quarters.

• ·FY2025 Adjusted EBITDA of $11.2M, up from $8.2M in FY2024.
• ·Cash provided by operating activities $9.3M in FY2025 vs $6.3M in FY2024.
• ·Tenth consecutive GAAP profitable quarter and 29th consecutive non-GAAP profitable quarter.
• ·User base grown from 4M to over 7M in under 3 years (+75%).
• ·Conference call held March 3, 2026 at 4:30 PM ET.

03-03-2026

Rigel Pharmaceuticals reported record Q4 2025 total revenues of $69.8 million (net product sales $65.4 million, +41% YoY from $46.5 million), driven by TAVALISSE ($45.6 million, +47%), GAVRETO ($10.2 million, +27%), and REZLIDHIA ($9.6 million, +29%); full-year revenues reached $294.3 million (net product sales $232.0 million, +60% YoY from $144.9 million) with TAVALISSE +52%, GAVRETO +146%, and REZLIDHIA +35%. However, total costs and expenses increased to $46.6 million in Q4 (+14% YoY) and $168.8 million for the year (+9% YoY), driven by higher R&D and personnel costs, though net income was $268.1 million in Q4 and $367.0 million for the year, boosted by a $245.9 million non-cash deferred tax benefit. The company anticipates 2026 total revenues of $275-290 million (net product sales $255-265 million) and positive net income.

• ·Enrollment ongoing in R289 Phase 1b dose expansion phase (up to 40 patients at 500 mg QD or BID); on track to complete enrollment and select Phase 2 dose in H2 2026, with preliminary data by end of 2026.
• ·R289 dose escalation: 33% (6/18) evaluable transfusion-dependent patients achieved RBC-TI ≥8 weeks at ≥500 mg QD.
• ·GAVRETO ARROW study: median OS 44.3 months overall, 62.4 months in US patients.
• ·Pralsetinib TAPISTRY study: ORR 67% (26/39) in RET fusion-positive solid tumors.
• ·FDA approved GAVRETO sNDA with boxed warning on Dec 22, 2025; met postmarketing commitment for AcceleRET-Lung.
• ·Michael P. Miller joined Board effective Feb 1, 2026.

03-03-2026

Transglobal Management Group, Inc. (formerly The Marquie Group, Inc.) entered into a Standby Equity Commitment Agreement with MacRab LLC on February 17, 2026, under which the investor committed to purchase up to $5M of the company's common stock at the company's discretion, priced at 85% of the average of the two lowest VWAPs over the five trading days following the clearing date, with a $0.001 minimum price per share and a 4.99% beneficial ownership cap. The company also entered a Registration Rights Agreement to register resale of the shares. No shares have been issued yet, and the agreements are filed as exhibits.

• ·Pricing based on average of the two lowest volume weighted average prices (VWAP) during the five trading days immediately following the applicable clearing date.
• ·Company controls timing and amount of sales, subject to agreement conditions.

03-03-2026

Valuence Merger Corp. I, a SPAC, entered into a convertible promissory note with VMCA Sponsor, LLC for principal up to $1.5M, interest-free, to fund operations prior to an initial business combination. The note matures on the earlier of the business combination closing or liquidation, with repayment limited to funds outside the trust account if no combination occurs, and is convertible at the payee's option into warrants at $1.50 each. No drawdowns have been specified, and the agreement includes standard trust waivers and no-prepayment terms.

• ·Note dated February 27, 2026
• ·Drawdowns funded within 1 business day of request, up to $1.5M total outstanding
• ·Conversion warrants identical to those issued in private placement at IPO
• ·Governed by New York law; no personal liability for Maker's officers/directors
• ·Payee waives claims against trust account

03-03-2026

Ward W. Woods informed Alphatec Holdings, Inc. of his retirement from the Board of Directors, effective February 27, 2026, for personal reasons with no disagreements on operations, policies, or practices; he also served on the Compensation Committee. In connection with his departure, the company entered a Vesting Acceleration Agreement fully vesting his unvested restricted stock units granted on June 11, 2025. The Board reduced its size from eight to seven directors on February 26, 2026.

• ·Vesting Acceleration Agreement filed as Exhibit 10.1
• ·Event reported on February 25, 2026; filing dated March 3, 2026

03-03-2026

Sana Biotechnology reported positive 12-month clinical data for UP421 in type 1 diabetes, advancing SC451 toward IND filing and Phase 1 trial in 2026, and preclinical progress for SG293 with first-in-human data expected this year; raised $133.7M in gross proceeds via equity financings extending cash runway into late 2026. However, cash position declined 9% YoY to $138.4M, Q4 net loss widened 20% to $58.8M due to higher success payment expenses, and FY recorded $44.6M impairment on manufacturing assets amid portfolio prioritization that cut R&D expenses 39% YoY but reflects scaled-back operations.

• ·Raised $126.4M net proceeds from equity financings in 2025 offsetting $143.8M cash used in operations.
• ·Non-cash R&D related success payments and contingent consideration expense of $29.4M in FY 2025 vs prior gains.
• ·Appointed Brian Piper as CFO in Q1 2026.
• ·Published preclinical data in Nature Biotechnology on fusogen for HSC gene editing.

03-03-2026

SoundThinking, Inc. reported record FY2025 revenues of $104.1M, up 2% YoY from $102.0M, with Q4 revenues increasing 6% to $24.8M; the company also went live with ShotSpotter in 10 new cities, 2 universities, and 11 expansions. However, gross profit declined 2% YoY to $56.6M (54% margin vs 57%), Adjusted EBITDA fell 12% to $12.6M (12% margin vs 14%), ARR was nearly flat at $95.4M starting 2026 (vs $95.6M), and revenue retention dropped to 99% from 105% due to the Chicago contract loss. FY2026 guidance was lowered to $109.0-111.0M revenue (6% YoY growth at midpoint) and 16-18% Adjusted EBITDA margin, with ARR expected to reach ~$110M by start of 2027.

• ·Total operating expenses FY2025 decreased 1% to $65.4M from $65.7M in FY2024.
• ·Q4 2025 operating expenses $15.1M vs $15.5M in Q4 2024.
• ·FY2025 GAAP net loss per share $(0.74) vs $(0.72) in FY2024.
• ·Revenue increase partially offset by ~$9M Chicago revenue in FY2024 not present in FY2025.
• ·Q4 revenue increase offset by ~$1.6M Chicago revenue in Q4 2024.

03-03-2026

Latham Group reported strong Q4 2025 net sales of $100.0M, up 14.5% YoY driven by fiberglass pools (+15%) and covers (+19%), though liners grew only 2% YoY; FY2025 net sales reached $545.9M, up 7.4% YoY outperforming a declining U.S. pool market, with covers up 22% but in-ground pools flat at +1%. Adjusted EBITDA surged 190% YoY to $10.5M in Q4 (10.5% margin, +630 bps) and 24% to $99.8M for FY (18.3% margin, +250 bps), despite Q4 net loss of $7.0M (improved from $29.2M prior); in Feb 2026 acquired Freedom Pools (expected +$20M sales, +$4M EBITDA), with 2026 guidance of $580-610M sales (+9% mid YoY) and $105-120M Adj EBITDA (+13% mid).

• ·Q4 2025 gross margin 28.0% (+340 bps YoY); FY 2025 gross margin 33.4% (+320 bps YoY)
• ·Net debt leverage ratio 2.1x at Dec 31, 2025
• ·FY 2026 Capex guidance $42-48M
• ·Conference call March 3, 2026 at 4:30 PM ET
• ·Acquisition of Freedom Pools closed February 26, 2026

03-03-2026

On February 13, 2026, the Board of Directors of Stoke Therapeutics, Inc. approved a discretionary bonus of $697,125 to Chief Executive Officer Ian F. Smith, based on strong clinical and financial performance following his appointment as interim CEO in March 2025 and permanent CEO in October 2025. The bonus represents his full target annual bonus amount for 2025, despite not participating in the annual bonus program, as corporate goals were achieved at 150% of target.

• ·Ian F. Smith appointed interim CEO in March 2025 and permanent CEO in October 2025
• ·Mr. Smith did not participate in the Company's 2025 annual bonus program

03-03-2026

Superior Group of Companies reported Q4 2025 net sales of $146.6 million, up 0.8% YoY from $145.4 million, with net income increasing 66% to $3.5 million (EPS $0.23) and EBITDA rising 19% to $8.6 million. However, full-year 2025 net sales were nearly flat at 0.1% growth to $566.2 million from $565.7 million, while net income declined 42% to $7.0 million (EPS $0.46) from $12.0 million (EPS $0.73), and EBITDA fell 24.5% to $25.7 million. The company issued 2026 guidance for net sales of $572-585 million (up 1-3%) and EPS of $0.54-0.66 (up 17-43%).

• ·Cash and equivalents increased to $23.7M from $18.8M YoY.
• ·Total debt (current + long-term) rose to $93.7M from $86.0M.
• ·Operating cash flow FY 2025 was $19.7M, down from $33.4M in 2024.
• ·Share repurchases totaled $10.1M in FY 2025.
• ·Cash dividends per share remained $0.56 for FY 2025, flat YoY.
• ·Conference call replay available through March 17, 2026.

03-03-2026

NeuroPace reported Q4 2025 total revenue of $26.6 million, up 24% YoY from $21.5 million, and full-year 2025 revenue of $100.0 million, up 25% YoY from $79.9 million, driven by 25-26% RNS System growth; gross margins improved significantly to 77.4% in Q4 (+200 bps YoY) and 77.2% for the year (+330 bps YoY). However, operating expenses rose to $22.3 million in Q4 (up from $19.8 million YoY) and $93.6 million for the year (up from $80.8 million), resulting in Adjusted EBITDA of ($5.0) million for FY2025 and guidance for ($9.0) to ($10.0) million in 2026 despite flat total revenue guidance of $98-100 million on a continuing operations basis (20-22% underlying RNS growth). The company reiterated 2026 outlook excluding DIXI Medical, which ceased operations early on December 31, 2025.

• ·Q4 2025 Adjusted EBITDA: $0.9 million (second consecutive positive quarter)
• ·FY 2025 Adjusted EBITDA: ($5.0) million
• ·Cash increased $1.0 million QoQ to $61.1 million as of Dec 31, 2025
• ·Q1 2026 revenue guidance: $21-22 million
• ·FY 2026 non-GAAP gross margin guidance: 81.5%-82.5%
• ·FY 2026 non-GAAP operating expenses guidance: $90-92 million
• ·NAUTILUS trial: 77% median seizure reduction at 18 months
• ·RNS System featured in over 80 presentations at AES meeting

03-03-2026

Enliven Therapeutics reported positive initial Phase 1b ENABLE trial data for ELVN-001 in 60 heavily pretreated CML patients, achieving cumulative MMR rates of 47% (80 mg QD, n=19) and 69% (60/120 mg QD, n=41), with DMR rates of 16% and 35%, respectively. The company ended 2025 with a strong $463M cash position, providing runway into H1 2029, and plans Phase 3 ENABLE-2 initiation in H2 2026. However, net loss widened to $103.7M for FY2025 from $89.0M in FY2024, driven by R&D expenses up 6% to $85.9M and G&A expenses up 42% to $33.8M.

• ·53% of patients received four or more unique prior TKIs; 67% prior asciminib, 32% prior ponatinib
• ·100% of patients achieving MMR maintained it in both dose cohorts
• ·Mid-2026 additional Phase 1 data presentation and FDA alignment on Phase 3 design
• ·Q4 2025 G&A expenses increased 110% YoY to $13.0M due to CEO transition stock-based compensation

03-03-2026

GitLab Inc. reported strong Q4 FY26 revenue of $260.4 million, up 23% YoY, and FY26 revenue of $955.2 million, up 26% YoY, with non-GAAP operating margins expanding to 21% and 17% respectively, alongside robust FY26 adjusted free cash flow of $219.6 million. However, GAAP operating margins remained negative at (2)% in Q4 and (7)% for FY26, Q4 GAAP net loss was $2.6 million versus prior year income, and Q4 operating cash flow declined to $45.8 million from $63.2 million. The board authorized a $400 million share repurchase program, reflecting confidence, while FY27 revenue guidance is $1,099-$1,118 million.

• ·Crossed $1B in ARR during FY26
• ·Q1 FY27 non-GAAP operating income guidance $32-$34M; non-GAAP diluted EPS $0.20-$0.21
• ·FY27 non-GAAP operating income guidance $129-$137M; non-GAAP diluted EPS $0.76-$0.80

03-03-2026

Blackstone Secured Lending Fund (BXSL) entered into a Tenth Supplemental Indenture with U.S. Bank Trust Company, National Association, issuing $400M in aggregate principal amount of 5.250% notes due September 4, 2029, which closed on March 3, 2026. The notes bear interest at 5.250% payable semi-annually starting September 4, 2026, are redeemable at the Fund's option, and rank as general unsecured obligations senior to subordinated debt but junior to secured debt and subsidiary obligations. The issuance includes covenants on asset coverage under the Investment Company Act and a change of control repurchase requirement at 100% of principal plus accrued interest.

• ·Notes mature on September 4, 2029, with interest payments semi-annually on March 4 and September 4 commencing September 4, 2026.
• ·Underwriting agreement dated February 26, 2026; offered pursuant to Registration Statement on Form N-2 (File No. 333-288640).
• ·Covenants require compliance with modified Section 18(a)(1)(A) asset coverage of the Investment Company Act.

03-03-2026

Quantum-Si reported Q4 2025 revenue of $0.5M, down 62% YoY from $1.2M, and full-year 2025 revenue of $2.4M, a 20% decline from $3.1M in 2024, with Q4 gross margin at 27% versus full-year 47%; however, Q4 operating expenses fell 32% YoY to $21.2M, full-year adjusted operating expenses decreased 13% to $86.3M, and adjusted EBITDA loss improved to negative $80.7M from negative $92.8M. The company announced a $425,000 list price for the Proteus platform, on track for year-end 2026 launch, but guided 2026 revenue to approximately $1.0M due to strategic placement programs and upgrade credits tempering near-term sales. Cash and equivalents totaled $215.8M as of Dec 31, 2025, providing runway into Q2 2028.

• ·One-time charges for legacy litigation and settlements totaled $18.7M in 2025.
• ·Cash runway extends into Q2 2028 based on $215.8M position.
• ·Class A common shares outstanding: 196.4M as of Dec 31, 2025 (up from 147.0M in 2024).

03-03-2026

RYTHM, Inc. reported fourth quarter 2025 revenue from continuing operations of $10.7 million, up 164% QoQ from $4.0 million, with gross profit of $8.0 million (75% margin) versus $1.4 million (34% margin) in the prior quarter. However, operating loss from continuing operations widened to $12.9 million, driven by an $8.5 million non-cash impairment charge. Full year revenue reached $17.3 million, including $7.8 million in licensing fees, but net loss was $33.3 million, an improvement from $41.7 million in 2024 despite ongoing cash burn from operations.

• ·Cash used in operating activities FY 2025: $23.5M versus $11.6M in FY 2024.
• ·Total assets as of Dec 31, 2025: $106.7M.
• ·1-for-15 reverse stock split on October 8, 2024.
• ·Potential federal prohibition on hemp-derived THC products effective November 2026.

03-03-2026

Plains All American Pipeline, L.P. executed a Third Amendment to its Credit Agreement on February 26, 2026, replacing Plains Midstream Canada ULC (PMCULC) as a borrower with Plains Canada Liquid Pipelines ULC (PCLPULC), while releasing PMCULC from all obligations under the loan documents upon full payment of its outstanding loans and obligations. The amendment was agreed upon by the borrowers, Bank of America, N.A. as Administrative Agent, and multiple lenders including Citibank, N.A., JPMorgan Chase Bank, N.A., and Wells Fargo Bank. No financial terms, commitment amounts, or other quantitative changes to the credit facility were disclosed.

• ·Original Credit Agreement dated August 20, 2021
• ·First Amendment dated August 22, 2022
• ·Second Amendment dated August 19, 2024
• ·Amendment requires satisfaction of conditions including KYC documentation, legal opinions from Richard McGee, Vinson & Elkins LLP, and Cox Taylor, and payment of PMCULC's outstanding obligations

03-03-2026

Box reported record Q4 FY26 revenue of $306M, up 9% YoY, and FY26 revenue of $1.18B, up 8% YoY, with RPO hitting a record $1.71B, up 17% YoY, and significant margin expansion to 10.2% GAAP and 30.6% non-GAAP operating margins in Q4. However, Q4 billings grew more modestly at 5% YoY, FY26 non-GAAP free cash flow increased only 3%, non-GAAP diluted EPS declined to $1.44 for the full year from $1.71 prior year, and GAAP operating margin for FY26 slightly dipped to 7.1% from 7.3%. Looking ahead, FY27 revenue guidance is $1.275B, up 8% YoY.

• ·Q4 short-term RPO up 12% YoY to $913.7M; long-term RPO up 22% YoY to $797.0M.
• ·Repurchased 4.4M shares for $126M in Q4 FY26; $59M remaining capacity.
• ·Customer wins/expansions include Robinhood Markets, Mayo Clinic, Novo Nordisk.
• ·Q1 FY27 guidance: revenue ~$304M (+10% YoY), non-GAAP EPS $0.36.
• ·FY27 guidance: GAAP operating margin 9.5%, non-GAAP 28%, non-GAAP EPS $1.55.

03-03-2026

Crinetics Pharmaceuticals, Inc. dismissed BDO USA, P.C. as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP (PwC) as the new firm on February 27, 2026, approved by the Audit Committee. BDO's reports on the fiscal years ended December 31, 2025 and 2024 contained no adverse opinions, qualifications, disagreements, or reportable events. BDO furnished a letter to the SEC dated March 3, 2026, agreeing with the company's statements.

• ·The company provided BDO's letter as Exhibit 16.1.
• ·No consultations with PwC occurred in fiscal years 2024-2025 or interim through February 27, 2026.

03-03-2026

MYR Group Inc. posted investor presentation materials for the 2025 Fourth Quarter on its website on March 3, 2026, under Item 7.01 Regulation FD Disclosure. Management may use these materials in meetings with the investment community during the quarter ending March 31, 2026. The presentation is furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.

• ·Presentation available at: https://investor.myrgroup.com/news-events/presentations
• ·Securities: Common Stock, $0.01 par value (MYRG) on Nasdaq Global Market

03-03-2026

Cricut, Inc. reported full-year 2025 revenue of $708.8 million, a less than 1% decline from $712.5 million in 2024, driven by a 5% drop in products revenue to $381.4 million offset partially by 5% growth in platform revenue to $327.4 million. Net income rose 22% to $76.7 million with gross margins expanding to 55.1% from 49.5%, paid subscribers grew over 4% to 3.09 million, and cash from operations reached $200.2 million; however, active users remained flat at 5.9 million, 90-day engaged users fell 3% to 3.7 million, and Q4 revenue declined 3% to $203.6 million with products down 8%. International revenue increased 8% to $169.7 million, representing 24% of total revenue.

• ·Authorized $50 million stock repurchase program with $41.3 million remaining.
• ·Expect profitable each quarter and positive cash flow from operations in 2026.
• ·Conference call scheduled for March 3, 2026 at 3:00 p.m. Mountain Time.

03-03-2026

Transact Technologies Incorporated filed an 8-K on March 3, 2026, disclosing amended and restated bylaws effective February 25, 2026, under Items 5.03 and 9.01. Key updates include authorizing remote communication for stockholder meetings, allowing the board to set annual meeting dates instead of a fixed first Thursday in May, and requiring stockholders owning 50% of voting power to call special meetings via written request. These changes modernize procedures for meetings, proxies, and director nominations without any disclosed financial impact.

• ·Notice of annual or special meetings: 10-60 days prior
• ·Stockholder list preparation: at least 10 days before meeting
• ·Proxy validity: up to 3 years unless specified otherwise
• ·Quorum: majority of stock issued and outstanding entitled to vote
• ·Registered office: City of Wilmington, County of New Castle, State of Delaware

03-03-2026

IBM filed an 8-K on March 3, 2026, under Items 5.03 and 9.01, attaching its bylaws as amended through March 1, 2026. The document details governance procedures including stockholder meetings (annual on the last Tuesday of April, special meetings callable by the Board, Chairman, or holders of at least 25% of shares), Board of Directors powers and composition, executive committees, officers, and other corporate matters. No financial metrics, performance changes, or material alterations to shareholder rights are specified in the filing.

• ·Bylaws originally adopted April 29, 1958
• ·Annual stockholder meeting held on last Tuesday of April each year (or next non-holiday)
• ·Stockholder meeting notice: 10-60 days in advance
• ·Quorum for stockholder meetings: majority of outstanding voting shares
• ·Special meetings limited to business specified in notice

03-03-2026

Ultra Clean Holdings, Inc. (UCTT) entered into a call option transaction with a Dealer to hedge its issuance of $525M aggregate principal amount of 0.00% Convertible Senior Notes due 2031, with an option for up to an additional $75M. The transaction is confirmed under the 2002 ISDA Equity Derivatives Definitions, with an Indenture dated March 3, 2026, between UCTT and U.S. Bank Trust Company, National Association as trustee. Key option terms include a Strike Price of $84.7450, Cap Price of $104.0725, Free Convertibility Date of December 16, 2030, and Expiration Date of March 15, 2031.

• ·Offering Memorandum dated February 25, 2026
• ·Trade Date: [_____] (to be specified)
• ·Effective Date: Closing date of initial Convertible Notes issuance
• ·Exchange: Nasdaq Global Select Market (symbol UCTT)
• ·Option Style: European
• ·Settlement Method: Default Net Share Settlement

03-03-2026

On March 2, 2026, Covista Inc. (formerly Adtalem Global Education Inc.) amended its credit agreement to incur $510 million in new 2026 Term Loans maturing March 2, 2033, with interest rate margins reduced by 0.50% (Term SOFR + 2.25% with 0.75% floor or ABR + 1.25%). Proceeds refinanced existing term loans and fully redeemed $404.95 million in 5.50% Senior Secured Notes due 2028 at 100% of principal plus accrued interest, satisfying and discharging the related indenture. No declines or flat performance noted in this debt refinancing event.

• ·Redemption notice for Notes sent by Trustee on February 13, 2026.
• ·Original Credit Agreement dated August 12, 2021; Indenture dated March 1, 2021.
• ·2026 Term Loans mature on March 2, 2033.

03-03-2026

Black Rock Coffee Bar reported strong Q4 2025 results with total revenue of $53.6M, up 25.3% YoY, same store sales growth of 9.3%, and 12 new stores opened, driving operating income to $1.8M from a $0.1M loss and Adjusted EBITDA up 52.4% to $6.5M. For FY2025, revenue grew 24.5% to $200.3M with SSS up 10.1% and 32 new stores, but operating income declined sharply to $0.9M from $6.0M while net loss widened 130.1% to $16.5M amid higher SG&A expenses at 20.6% of revenue versus 15.7% prior year.

• ·Cash and cash equivalents $28.4M and total debt $26.7M as of Dec 31, 2025; repaid $30.1M under $50M term loan, leaving $19.9M outstanding.
• ·FY2026 outlook: 36 new store openings, total revenue $255-257M, mid-single digit SSS growth, Adjusted EBITDA $33.5-34.5M, CapEx $40-41M.
• ·Conference call on March 3, 2026 at 5:00 p.m. ET; replay available until March 17, 2026.

03-03-2026

AnaptysBio reported strong Q4 2025 collaboration revenue of $108.2M, up 151% YoY from $43.1M, driven by Jemperli royalties increasing 89% to $32.7M and milestones including a $75M payment, resulting in Q4 net income of $49.6M versus a $21.8M loss prior year. Full-year 2025 revenue rose 157% to $234.6M, narrowing FY net loss to $13.2M from $145.2M, with the spin-off of biopharma operations into First Tracks Biotherapeutics on track for Q2 2026. However, cash and investments fell 26% YoY to $311.6M due to $130.6M in operating activities and $68.6M share repurchases, while G&A expenses increased 55% QoQ and 20% YoY to $15.8M/$50.7M amid separation costs.

• ·Phase 1b enrollment ongoing for ANB033 in celiac disease (60 patients, top-line Q4 2026) and initiated in eosinophilic esophagitis (50 patients, top-line 2027).
• ·Rosnilimab Phase 2b data presented at ACR Convergence 2025; update on RA advancement expected Q2 2026.
• ·FDA accepted BLA for imsidolimab in GPP (target action Dec 12, 2026).
• ·GSK trials for Jemperli: AZUR-1 top-line 2026, AZUR-2 2028, AZUR-4 Q4 2026, JADE 2028.
• ·Expected >$390M annualized Jemperli royalties at GSK peak sales >$2.7B as early as 2029.
• ·Sagard debt paydown anticipated by end Q2 2027.

03-03-2026

Ascent Industries Co. reported Q4 2025 net sales from continuing operations up 3.9% YoY to $18.8M, driven by higher volumes but offset by lower prices; however, gross profit fell 2.9% to $3.4M (18.3% margin vs 19.2%), resulting in a net loss of $1.0M versus $0.2M income, and Adjusted EBITDA worsened to -$1.1M. For FY2025, net sales declined 7.3% to $74.9M amid lower volumes, but gross profit rose 61.0% to $17.2M (23.0% margin vs 13.2%), net loss narrowed to $5.6M from $12.6M, and Adjusted EBITDA improved to -$0.6M from -$4.7M, following divestitures of BRISMET on April 4, 2025, and ASTI on June 30, 2025.

• ·Cash increased to $57.6M as of Dec 31, 2025 from $16.1M, with no debt under revolving facilities.
• ·Total assets $111.9M as of Dec 31, 2025 (down from $147.3M), reflecting divestitures.
• ·Share repurchases: 745,524 shares at avg $12.26 for $9.2M in FY2025; 19,749 shares at avg $13.23 for $0.3M in Q4.

03-03-2026

On March 3, 2026, Lindblad Expeditions Holdings, Inc. acquired an additional 5% interest in its subsidiary Natural Habitat, Inc. from Ben Bressler, Founder and CEO of Natural Habitat, for $16.6 million, increasing the Company's ownership to 95%. Mr. Bressler retains a 5% noncontrolling interest subject to an existing put/call arrangement under the stockholders' agreement. No financial performance metrics or period comparisons were reported.

• ·Acquisition resulted from exercise of put right by Mr. Bressler pursuant to original stockholders' agreement from prior Natural Habitat acquisition.

03-03-2026

Arbutus Biopharma and Genevant Sciences announced a $2.25B global settlement with Moderna resolving patent infringement claims over LNP technology used in COVID-19 vaccines, including $950M upfront payment in July 2026 and $1.3B contingent on a favorable appellate ruling on Section 1498. Moderna consents to judgment of infringement and no invalidity on four patents, receiving a global non-exclusive license. However, the $1.3B payment remains uncertain pending the appeal, and Pfizer/BioNTech litigation continues despite a favorable Markman ruling in September 2025.

• ·Arbutus evaluating return of capital to shareholders for Q3 2026 in conjunction with upfront payment.
• ·Roivant hosting investor conference call on March 3, 2026 at 4:45 p.m. ET.
• ·Pfizer/BioNTech litigation ongoing in the US following favorable Markman ruling in September 2025.

03-03-2026

RLI Corp. entered into an Amended and Restated Credit Agreement with PNC Bank, National Association, effective February 26, 2026, which refinances the existing agreement dated March 30, 2023, and increases the revolving commitments, though specific commitment amounts are not disclosed. Pricing is tiered based on leverage ratio, with SOFR spreads from 1.375% (Level I, <=0.20x) to 1.875% (Level III, >0.30x) and commitment fees from 0.20% to 0.30%. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Agreement amends and restates Existing Credit Agreement dated March 30, 2023.
• ·Pricing Dates begin for fiscal quarters ending on or after March 31, 2026.
• ·Subsidiaries listed in Schedule 3.08 (not detailed in excerpt).

03-03-2026

MySize, Inc. received a Nasdaq notice on March 2, 2026, for its common stock closing bid price below $1.00 for 30 consecutive trading days, with 180 days until August 31, 2026, to regain compliance by achieving $1.00 for 10 consecutive business days; non-compliance risks delisting but does not immediately affect trading or operations. The company reported preliminary unaudited 2025 revenue of approximately $10 million, with Orgad at ~40% gross margins providing stability, while new subsidiary 10peaks generated ~$150,000 in revenue at ~65% gross margins but represents a small portion of total revenue. Management estimates 10peaks could reach $3 million in annual revenue based on current assumptions.

• ·10peaks formed in September 2025 as a wholly owned subsidiary operating in Israel, Greece, Cyprus, and Malta.
• ·To regain Nasdaq compliance, common stock must close at or above $1.00 per share for 10 consecutive business days.
• ·Potential for second 180-day compliance period if initial deadline missed and other listing standards met.

03-03-2026

ABVC BioPharma filed its 2025 Form 10-K on March 3, 2026, reporting total assets of $21.06 million as of December 31, 2025, a 179% YoY increase from $7.54 million in 2024, primarily driven by net property and equipment surging to $12.84 million from $0.51 million due to strategic land acquisitions in Taiwan. The company advanced its asset-backed licensing model by licensing CNS, oncology, and ophthalmology programs to subsidiaries AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation, reducing direct clinical burn while retaining economics. No operating results or declines were highlighted, emphasizing balance sheet strengthening.

• ·Research institutions in network: Stanford University, University of California at San Francisco, Cedars-Sinai Medical Center
• ·Longtan land held by related party pending title transfer
• ·Puli land title transfer under government review as of press release date

03-03-2026

Champion Homes, Inc. (SKY) appointed Timothy Kingston as Chief Accounting Officer and principal accounting officer effective March 9, 2026, following Board action on March 2, 2026. Incumbent Timothy Burkhardt will step down as principal accounting officer on the effective date but continue as Vice President and Controller until his retirement on May 31, 2026, assisting in the transition. Mr. Kingston, aged 48 and a CPA with prior experience at Kellanova and Zimmer Biomet, will receive an annual base salary of $365,000, a target cash bonus of 50% of base salary, and long-term incentives at 85% of base salary starting fiscal 2027.

• ·Timothy Kingston previously served as Vice President, Assistant Corporate Controller at Kellanova (formerly Kellogg) from August 2020 to February 2026.
• ·No arrangements, family relationships, or material interests under Item 404(a) of Regulation S-K for Mr. Kingston.
• ·Filing signed by Laurel Krueger on March 3, 2026.

03-03-2026

On March 2, 2026, Group 1 Automotive, Inc. entered into a Second Amendment to Daryl Kenningham's Incentive Compensation Agreement, restructuring severance benefits to 1.5 times the sum of his base salary and target annual bonus, plus 18 months of COBRA coverage and a pro-rated bonus for qualifying terminations. Benefits increase to 2.0 times the sum and 24 months of COBRA if termination occurs within six months of a Corporate Change. Severance is payable in a lump sum on the first day of the seventh month following separation, subject to compliance with covenants and execution of a release.

• ·Severance benefits are Mr. Kenningham’s sole and exclusive remedy against the Company.
• ·Full Second Amendment to be filed in next Quarterly Report on Form 10-Q.

03-03-2026

The J. M. Smucker Company finalized a Separation Agreement with John Brase, its former President and Chief Operating Officer, effective February 26, 2026, following his prior announcement as no longer an executive officer on February 10, 2026. The agreement provides severance benefits including a $1.185M lump sum (18 months base salary), $611,885 pro rata FY2026 incentive payment, vesting of select unvested restricted stock units, options, and pro-rated performance units, plus $196,000 in additional lump sums for medical insurance, relocation, and outplacement services, all payable April 17, 2026. Terms align with the company's Executive Severance Plan and include non-compete, non-solicitation, and confidentiality obligations.

• ·Vesting of unvested restricted stock awards granted June 15, 2023 (third tranche) and April 14, 2020 (full on Jan 27, 2028); remaining RSUs forfeited.
• ·Vesting of unvested option award from June 15, 2023 (third tranche); remaining options forfeited; vested options exercisable by May 10, 2026.
• ·Pro-rated vesting eligibility for performance units granted June 15, 2023 and August 13, 2024 (those with at least one full performance year); based on completed months and actual 3-year performance; remaining forfeited.
• ·Separation Agreement to be filed as exhibit to 10-K for period ending April 30, 2026.

03-03-2026

Old Dominion Freight Line, Inc. filed an 8-K on March 3, 2026, under Items 7.01 and 9.01, disclosing a press release that provides an update on certain operating metrics for the first quarter of 2026. The press release is furnished as Exhibit 99.1. No specific metrics or financial data are detailed in the filing itself.

• ·Filing pertains to first quarter of 2026 operating metrics update.
• ·Securities registered: Common Stock ($0.10 par value) under symbol ODFL.

03-03-2026

Pulse Biosciences, Inc. posted an updated investor presentation on its website on March 3, 2026, disclosing certain summary financial information, a description of its next-generation nPulse cardiac catheter under development, and a strengthened focus on EP cardio ablation product and clinical development following unprecedented clinical outcomes data in the Company's EU feasibility study. The Investor Deck is attached as Exhibit 99.1 and available at www.pulsebiosciences.com under 'Investors,' and may be used in presentations to investors and analysts. The information is summary only, as of March 2026, and subject to risks and forward-looking statements.

03-03-2026

Delcath Systems, Inc. announced on March 3, 2026, the publication of CHOPIN clinical trial results in The Lancet Oncology via a press release furnished as Exhibit 99.1. The filing highlights this milestone under Item 8.01 Other Events, signed by CEO Gerard Michel. No financial or quantitative performance data was disclosed.

03-03-2026

Simmons First National Corporation and Simmons Bank amended the Executive Change in Control Severance Agreement for James M. Brogdon on February 27, 2026, increasing the termination compensation multiplier from 2 times to 3 times his Base Period Income (originally set in the July 30, 2021 agreement). This change enhances potential severance payout in a change-of-control scenario but increases potential costs to the company. The full amendment is attached as Exhibit 10.1.

• ·Agreement amendment filed under Items 5.02 and 9.01 of Form 8-K
• ·Common stock trades as SFNC on Nasdaq Global Select Market, par value $0.01 per share

03-03-2026

Howmet Aerospace Inc. closed a $1.2B public notes offering on March 3, 2026, comprising $400M 3.750% notes due 2028, $300M 3.900% notes due 2029, and $500M 4.750% notes due 2036, with net proceeds plus $600M borrowings and cash on hand to fund the $1.8B purchase price for the Proposed CAM Acquisition from Stanley Black & Decker, Inc. The 2036 Notes are subject to special mandatory redemption at 101% of principal if the acquisition does not close by the Special Mandatory Redemption End Date under the December 22, 2025 Purchase Agreement. No period-over-period financial metrics are reported.

• ·Purchase Agreement dated December 22, 2025 between Stanley Black & Decker, Inc. and Howmet Aerospace Inc.
• ·Underwriting Agreement dated February 17, 2026.
• ·Interest payments: 2028 Notes semi-annually on March 3 and September 3 (commencing September 3, 2026); 2029 and 2036 Notes semi-annually on April 15 and October 15 (commencing October 15, 2026).
• ·Optional redemption prior to maturity at greater of 100% principal or discounted present value plus 10 bps (2028/2029 Notes) or 15 bps (2036 Notes).

03-03-2026

On March 3, 2026, HA Sustainable Infrastructure Capital, Inc. (HASI) redeemed all $450 million outstanding principal amount of its 8.000% senior notes due 2027 using a portion of the proceeds from its recent issuances of $600 million 7.125% green junior subordinated notes due 2056 and $400 million 6.000% green senior unsecured notes due 2036. This refinancing replaces higher-coupon, shorter-term debt with lower-coupon, longer-term green notes, potentially reducing interest costs but involving subordinated debt and net debt increase from the $1 billion issuance.

• ·Common Stock trades on New York Stock Exchange under symbol HASI
• ·Principal executive offices: One Park Place, Suite 200, Annapolis, Maryland 21401

03-03-2026

On February 27, 2026, The Walt Disney Company entered into a new 364-Day Credit Agreement for up to $5.25B (replacing the February 28, 2025 facility) and a new Five-Year Credit Agreement for up to $4B (replacing the March 4, 2022 facility), both unsecured with guarantees from TWDC Enterprises 18 Corp. These facilities support commercial paper borrowings and general corporate purposes, with maturities on February 26, 2027 (extendable to 2028) and February 27, 2031, respectively. An amendment to the March 1, 2024 Credit Agreement excluded FuboTV Inc. as an entity.

• ·Credit Agreements include customary covenants such as financial statement delivery, tax payments, and maintenance of existence; require minimum EBITDA to Interest Expense ratio of 3.00 to 1.00.
• ·Borrowings bear interest at Term SOFR (Dollars), EURIBOR (Euro), TIBOR (Yen), or Daily Simple SONIA (Sterling) plus spread of 0.625%-1.000%, or Base Rate + 0.000%.
• ·Excludes certain entities related to Hong Kong Disneyland, Shanghai Disney Resort, and FuboTV from representations, covenants, or events of default.
• ·Advances may be prepaid without penalty (except breakage costs); mechanism to replace benchmarks if unavailable.

03-03-2026

Inno Holdings Inc. (INHD) held its virtual 2026 Annual Stockholders Meeting on March 2, 2026, with 4,660,788 shares represented, achieving a 55.40% quorum of the 8,413,224 outstanding shares as of the February 5 record date. All six proposals passed overwhelmingly, including the election of directors Ding Wei, Mengshu Shao, Yufang Qu, Tao Tu, and Yongbo Mo; ratification of JWF Assurance PAC as auditor for FY ending September 30, 2026; increasing authorized common shares to 1,000,000,000; authorizing board discretion for reverse stock splits (1-for-2 to 1-for-4000 within 2 years); approving the 2026 Omnibus Incentive Plan; and adjournment authority.

• ·Proposal 2 (auditor ratification): 4,540,787 For (89.0% of votes cast), 50,651 Against, 69,349 Abstentions.
• ·Proposal 3 (increase authorized shares): 4,476,419 For (96.1% of votes cast), 178,586 Against, 5,781 Abstentions.
• ·Proposal 4 (reverse split authority): 4,481,647 For (96.1% of votes cast), 172,918 Against, 6,221 Abstentions.
• ·Proposal 5 (Omnibus Incentive Plan): 4,486,587 For (96.3% of votes cast), 166,621 Against, 7,579 Abstentions.

03-03-2026

Star Equity Holdings, Inc., through its subsidiary Alliance Drilling Tools, LLC, completed a sale and leaseback transaction for property in Evanston, Wyoming, to Pasture Drive Holdings, LLC for $1.7M on February 27, 2026. The company entered into a 20-year triple net lease with initial monthly base rent of $12,390, guaranteed by the parent company, covering all property expenses. The company anticipates closing two additional sale and leaseback transactions in Texas and Utah.

• ·ADT Wyoming PSA originally dated December 16, 2025, with exhibits filed in prior 8-K on December 17, 2025.
• ·Lease term: 20 years from closing, with four optional 5-year extensions.
• ·Two additional sale and leaseback transactions in Texas and Utah anticipated to close per agreements filed December 17, 2025.

03-03-2026

First Citizens BancShares, Inc. issued and sold $500M aggregate principal amount of its 4.869% Fixed-to-Floating Rate Senior Notes due 2032 on March 3, 2026, in a public offering. The notes were issued pursuant to a senior base indenture dated March 12, 2025, as supplemented, and an underwriting agreement dated February 25, 2026, with J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives. No period-over-period financial comparisons are provided in the filing.

• ·Registration Statement on Form S-3 filed August 14, 2024 (File No. 333-281553)
• ·Prospectus Supplement dated February 25, 2026, filed February 26, 2026
• ·Senior Base Indenture dated March 12, 2025
• ·Second Supplemental Indenture dated March 3, 2026

03-03-2026

Gaxos.ai Inc. (GXAI) acquired a 19.99% stake in America First Defense (AFD), a US-based defense technology company developing a detachable counter-drone system for neutralizing hostile UAVs via cyber attacks and a biomimetic soft robotics platform for low-detection operations. The acquisition provides Gaxos exposure to emerging US defense technologies targeting Department of Defense, Homeland Security, border security, and critical infrastructure markets. CEO Vadim Mats stated it positions Gaxos at the intersection of AI, defense innovation, and national security priorities with long-term commercial potential.

• ·Filing date: March 03, 2026
• ·SEC Items reported: 1.01 (Material Agreement Entry), 8.01, 9.01
• ·AFD targets: Department of War, Department of Homeland Security, border security, maritime security, municipal safety, critical infrastructure

03-03-2026

FACT II Acquisition Corp., a $175M SPAC, announced a definitive business combination with Precision Aerospace & Defense Group, Inc. (PAD) on December 1, 2025, positioning PAD's capabilities in non-destructive testing, precision machining, and sustainment services amid strong aerospace & defense demand and supply constraints, exemplified by Boeing's $567.3B commercial and $84.8B defense backlog as of December 31, 2025. Public peers like TransDigm, HEICO, and others saw EV/EBITDA multiples expand 20-57% from September 2025 to January 2026, reflecting market premiums for reliable suppliers. No negative performance metrics were reported in the filing.

• ·PAD founded in 2016, headquartered in Overland Park, Kansas, with AS9100-certified and ITAR-registered facilities.
• ·FACT formed in 2024, headquartered in New York, New York; units, shares, and warrants listed on Nasdaq (FACTU, FACT, FACTW).
• ·Registration statement on Form S-4 filed with SEC for the proposed business combination.

03-03-2026

SWK Holdings Corp is proposing a three-step merger where SWK merges into Acquisition Sub (a subsidiary of Intermediary Sub), followed by mergers into Intermediary Sub and then RWAY, with SWK stockholders eligible to receive RWAY common stock per the Exchange Ratio or cash equal to SWK Per Share NAV, plus a pro rata share of a $9M guaranteed cash payment from the Adviser. Total transaction costs are estimated at $6.7M for RWAY and $3.2M for SWK. Pro forma annual expenses for the combined RWAY increase to 16.98% of net assets (from RWAY's actual 16.07%), driven by higher management (3.42% vs 3.11%) and incentive fees (2.83% vs 2.59%), though other expenses slightly decline (1.59% vs 1.68%).

• ·Data based on information as of September 30, 2025.
• ·Exchange Ratio determined within two days prior to Effective Time, subject to anti-dilution adjustments.
• ·RWAY intends quarterly dividends post-merger, consistent with current practice.
• ·SWK Investor Relations contact: (778) 323-0959.

03-03-2026

Bath & Body Works, Inc. issued a notice of redemption on March 3, 2026, for any and all outstanding 6.694% Senior Notes due 2027, with the redemption date set for April 10, 2026. The redemption price will be the greater of 100% of the principal amount or the present value of remaining scheduled payments discounted at the applicable treasury rate plus 50 basis points, plus accrued interest to the redemption date. No specific principal amount outstanding was disclosed in the filing.

• ·Common Stock: $0.50 par value, traded as BBWI on The New York Stock Exchange
• ·Company address: Three Limited Parkway, Columbus, OH 43230
• ·IRS Employer Identification No.: 31-1029810

03-03-2026

On February 25, 2026, the Compensation Committee of Target Hospitality Corp. adopted new forms of Executive Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) Agreements under the 2019 Incentive Plan for awards to executive officers on or after that date, with terms substantially similar to prior versions. The Committee granted PSUs to three executives to motivate, incentivize, and retain them: Troy Schrenk (400,000 PSUs), Brendan Dowhaniuk (300,000 PSUs), and Heidi Lewis (175,000 PSUs). PSU vesting is based equally on Total Shareholder Return (TSR) and Adjusted EBITDA performance, ranging from 0% to 200% of target levels over the performance period.

• ·New RSU and PSU Agreements filed as Exhibits 10.1 and 10.2; specific PSU grant agreements as Exhibit 10.3.
• ·PSU Agreements similar to those filed in February 28, 2025 8-K (Exhibits 10.3, 10.4, 10.5, 10.6).

03-03-2026

Fuel Tech reported Q4 2025 consolidated revenues of $7.2M, up 37% YoY, driven by 37% growth in both FUEL CHEM ($4.9M) and APC ($2.4M) segments with gross margins expanding to 44.6%; full year 2025 revenues rose 6% to $26.7M, fueled by 28% FUEL CHEM growth, though APC revenues declined YoY. Despite margin improvements to 46.4% FY and a strong balance sheet with $32M in cash/investments and no debt, net loss widened FY to $(2.3M) from $(1.9M) with Adjusted EBITDA loss also deteriorating to $(2.7M) from $(2.2M). APC backlog grew to $7.0M while pursuing a $75-100M data center pipeline.

• ·Q4 2025 SG&A expenses $4.2M (57.3% of revenues) vs $3.9M (74.7%) prior year.
• ·FY 2025 SG&A expenses $14.1M (52.7% of revenues) vs $13.8M (54.8%) prior year.
• ·Conference call scheduled for March 4, 2026 at 10:00 am ET.
• ·DGI demonstration at fish hatchery to conclude Q2 2026; wastewater rental through Q3 2026.
• ·New FUEL CHEM demonstration commenced November 2025, potential $2.5-3.0M annual revenue.

03-03-2026

LM Funding America, Inc. entered into a new $11 million loan (February 2026 Loan) with Galaxy Digital LLC on February 27, 2026, using the proceeds to repay the prior $11 million January 2026 Loan under the Master Digital Currency Loan Agreement; the new loan is secured by Bitcoin collateral and due on April 24, 2026. This continues a pattern of rolling over short-term $11 million loans originally drawn in October 2025 and refinanced in January 2026, with no change in principal amount. The filings disclose no financial performance metrics or other material changes.

• ·October 2025 Loan drawn on October 30, 2025, originally due January 30, 2026
• ·January 2026 Loan drawn on January 28, 2026, due February 27, 2026
• ·February 2026 Loan due April 24, 2026
• ·All loans secured by Company-owned Bitcoin collateral

03-03-2026

Mayville Engineering Company (NYSE: MEC) reported Q4 2025 net sales of $134.3 million, up 10.7% YoY due to the Accu-Fab acquisition, strong growth in Data Center & Critical Power (from $4.3M to $20.4M), Construction & Access (+13.1%), and Powersports (+19.7%), but declines in Commercial Vehicle (-18.6% to $38.4M) and Military (-9.9% to $6.7M), with Agriculture flat at $7.7M. Adjusted EBITDA fell to $6.3 million (4.7% margin) from $9.2 million (7.6%), reflecting project launch costs and inefficiencies, resulting in a net loss of $4.4 million. For full-year 2025, net sales declined 6.0% to $546.5 million with a net loss of $8.1 million, though Adjusted EBITDA was $47.1 million (8.6% margin); FY 2026 guidance anticipates sales of $580-620 million and Adjusted EBITDA of $50-60 million amid ongoing legacy market softness.

• ·Q1 2026 guidance: Net sales $137-143M (vs Q1 2025 $135.6M), Adjusted EBITDA $5-7M (vs $12.2M)
• ·FY 2026 guidance: Free Cash Flow $25-35M, capex $15-20M
• ·Net debt to TTM Adjusted EBITDA ratio 3.7x as of Dec 31, 2025
• ·Accu-Fab expected to generate $40-50M incremental revenue in 2026
• ·Conference call scheduled for March 4, 2026 at 10:00 a.m. ET

03-03-2026

On February 25, 2026, Babcock & Wilcox Enterprises, Inc. entered into the Tenth Amendment to its Credit Agreement originally dated January 18, 2024, which increases borrowing availability based on inventory and receivables, extends the maturity date to January 18, 2028, suspends the $3M PBGC Reserve (with re-imposition possible on January 1, 2027 if a $3M installment is not paid by September 15, 2026), modifies deposit account covenants, and releases BRC Group Holdings, Inc. as a guarantor. These changes improve liquidity and flexibility without any reported declines in terms. No prior period financial metrics are provided for comparison.

• ·Credit Agreement originally dated January 18, 2024
• ·Registrant address: 1200 EAST MARKET STREET, SUITE 650, AKRON, OHIO 44305
• ·Telephone: (330) 753-4511
• ·IRS Employer Identification No.: 47-2783641
• ·Commission File Number: 001-36876

03-03-2026

U.S. Physical Therapy, Inc. reported strong FY 2025 results with adjusted EBITDA up 16.1% YoY to $95M from $81.8M, net revenue up 16.3% (PT +16%, injury prevention +18%), and operating income +18.4%, despite 2.9% Medicare rate reductions. Q4 2025 adjusted EBITDA rose $3M YoY to $24.8M, PT revenues increased $20M to $173.8M, and visits per clinic per day hit a record 32.7 amid 11.2% total visit growth. Looking ahead, new hospital partnerships are expected to deliver at least $14M EBITDA lift in 2027 (USPH share >$7M post-minority interest) across 70 clinics.

• ·Seven consecutive quarters of record visits per clinic per day through Q4 2025.
• ·PT operating costs down $0.50 per visit in Q4 2025 YoY and up only 1.1% for FY 2025.
• ·Recent acquisitions: Pacific Northwest PT team, home care addition, injury prevention team strengthening NYC presence.
• ·Two new long-term hospital arrangements phasing in mid-2026 for 70 clinics.

03-03-2026

RYAM reported Q4 2025 net sales of $417M, down 1% YoY from $422M, and a loss from continuing operations of $21M, worsening $5M from $16M in Q4 2024, with Adjusted EBITDA of $46M also down $5M YoY. While Cellulose Specialties sales rose 2% to $249M and Biomaterials increased 25% to $10M, Paperboard sales fell 27% to $44M and High-Yield Pulp declined 13% to $28M. Full-year revenue reached $1.5B with Adjusted EBITDA of $133M, but cash from operations was $24M and Adjusted Free Cash Flow was negative $88M.

• ·Q4 2025 global liquidity includes $75M cash, $72M ABL borrowing capacity, $10M France factoring availability
• ·Conference call scheduled for March 4, 2026 at 9:00 a.m. ET
• ·Non-operating charges in Q4 2025: $3M AGE project, $2M pension settlement loss, $1M SWEN put option remeasurement

03-03-2026

On February 26, 2026, the Compensation Committee of Anteris Technologies Global Corp. approved a one-time discretionary grant of restricted stock units (RSUs) valued at $500,000 to Chief Financial Officer Matthew McDonnell, effective March 4, 2026, under the company's Equity Incentive Plan. The RSUs vest one-third annually over three years, subject to continued employment, with accelerated vesting upon death, disability, or certain change in control events. This special award recognizes Mr. McDonnell's exemplary service and does not affect his target 2026 annual equity awards.

• ·RSUs to be determined by dividing $500,000 by the March 4, 2026 closing price of AVR common stock.
• ·Upon vesting, RSUs settle in CHESS depositary interests.
• ·Filing signed by Wayne Paterson on March 3, 2026.

03-03-2026

bioAffinity Technologies, Inc. issued a press release announcing the presentation of a poster titled 'Sputum as a Diagnostic Tool for the Treatment of Asthma' at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 annual meeting in Philadelphia, PA, on March 1, 2026. The poster highlights the company's development of clinical diagnostics to assist physicians in matching asthma and COPD patients with effective therapies and monitoring inflammatory changes to improve outcomes and reduce healthcare costs. No financial metrics or performance comparisons were reported.

• ·Presentation occurred on March 1, 2026, at AAAAI 2026 annual meeting in Philadelphia, PA.
• ·Press release (Exhibit 99.1) and poster (Exhibit 99.2) incorporated by reference.

03-03-2026

Hyster-Yale reported full-year 2025 revenue of $3.8B, down 13% YoY from $4.3B, with an operating loss of $22M versus prior profit of $245M, driven by lower volumes and $100M in gross tariff costs. Q4 revenue declined 14% YoY to $923M and 6% QoQ, resulting in a $37M operating loss including $40M tariffs, though bookings strengthened 35% YoY and 42% sequentially to $540M, signaling potential demand recovery, and Q4 operating cash flow rose to $57M from inventory efficiencies. For 2026, moderate full-year operating profit is expected with H2 revenue growth offsetting a small H1 loss.

• ·Lift Truck backlog $1.28B, down 34% YoY and 5% QoQ.
• ·Net debt/Adjusted EBITDA ratio increased to 5.3x as of Dec 31, 2025 from 1.1x prior year.
• ·Inventory declined $185M YoY excluding FX and tariff impacts; $105M QoQ.
• ·Working capital 19% of sales, improved $60M QoQ.

03-03-2026

Iterum Therapeutics plc requested a hearing before a Nasdaq Hearings Panel on March 3, 2026, staying a delisting suspension scheduled for March 5, 2026, due to failure to maintain a $1.00 minimum bid price per share. The company also fails to meet Nasdaq's $35M Minimum MVLS Requirement and must regain compliance by June 9, 2026, with no assurance of success. It is evaluating strategic alternatives, including potential wind-down, bankruptcy, or asset sales, noting shareholders are unlikely to receive any meaningful return.

• ·Delisting determination letter received on February 24, 2026.
• ·Previous compliance period for MVLS: 180 calendar days until June 9, 2026.
• ·Referenced risk factors in 10-Q for quarter ended September 30, 2025, filed November 14, 2025.

03-03-2026

Eastern Company reported Q4 2025 net sales of $57.5M, down 13.7% YoY from $66.7M, with net income of $1.2M and adjusted EPS of $0.31; full-year 2025 net sales fell 9% to $249.0M from $272.8M, net income declined 57% to $6.0M, though adjusted EBITDA was $19.4M. While gross margins held nearly flat at 22.8% in Q4 (vs 23.0% YoY) and the company achieved $4M in annualized cost savings, mitigated $10M in tariffs, reduced debt by $8.7M, and secured a new $100M credit facility, backlog dropped 10.5% to $81.1M and selling expenses rose as a percentage of sales.

• ·Q4 adjusted EBITDA $4.6M vs $5.8M YoY.
• ·FY SG&A expenses flat YoY but included $2.5M restructuring charges.
• ·Conference call scheduled for March 4, 2026 at 9:00AM ET.

03-03-2026

Xanadu Quantum Technologies Inc. is proceeding with a de-SPAC business combination with Crane Harbor Acquisition Corp., agreed on November 3, 2025, expected to close late Q1 or early Q2 2026, providing Newco (Xanadu Quantum Technologies Limited) with approximately $500M in gross proceeds ($225M from trust assuming no redemptions, $275M PIPE). Shares will list on Nasdaq and TSX, but employees face a 180-day lock-up post-closing and loss of CCPC tax status, impacting option exercises and future tax treatments. Last day for pre-public option exercises is March 16, 2026.

• ·Options expire at end of 10-year term or upon employment termination.
• ·Administrative freeze on cap table starts March 16, 2026; no exercises during freeze.
• ·Migration from Carta to Shareworks by Morgan Stanley post-lock-up.
• ·No ESPP initially post-listing.

03-03-2026

Fortitude Gold reported 2025 annual results with net sales declining 51% YoY to $18.4M from $37.3M, driven by sharply lower gold production of 5,236 oz (-68% YoY) and sales of 5,774 oz (-64% YoY), though higher realized gold prices of $3,235/oz (+37% YoY) provided some offset. All-in sustaining costs rose significantly to $1,697/oz (+76% YoY), cash balance dropped to $4.7M from $27.1M, and net income was a modest $0.4M versus a $2.0M loss in 2024. Subsequent events include a $12M private placement and a $40M East Camp Douglas joint venture with Hawthorne Land & Minerals.

• ·Ore mined 145,868 tonnes in 2025 (down from 447,304 tonnes in 2024); gold grade 0.39 g/t (down from 0.57 g/t).
• ·Total assets $136.2M at Dec 31 2025 (up from $122.1M); shareholders' equity $104.4M (down from $108.1M).
• ·Mine gross profit $10.0M in 2025 (down from $18.3M); 611 oz gold rounds/bullion inventory at year-end.
• ·Golden Mile Project permitting estimated Q2 2027; East Camp Douglas EA by H2 2026.

03-03-2026

Diamond Hill Investment Group, Inc. held a special shareholder meeting on March 3, 2026, where shareholders overwhelmingly approved the Merger Agreement with First Eagle Investment Management, LLC's subsidiary, Soar Christopher Holdings, Inc., with 1,911,619 votes for, 3,201 against, and 1,327 abstentions out of 1,916,147 shares present (70.82% quorum of 2,705,580 outstanding shares). The advisory compensation proposal also passed with 1,744,220 votes for versus 144,799 against and 27,128 abstentions. The merger is expected to close in Q2 2026, subject to customary conditions including client consents.

• ·Record date for special meeting: January 27, 2026
• ·Proxy statement filed with SEC on January 28, 2026
• ·Merger expected to close in second quarter of 2026, pending client consents and other conditions
• ·No broker non-votes for either proposal

03-03-2026

WEBTOON Entertainment Inc. reported full year 2025 revenue of $1.4B, up 2.5% YoY (3.9% constant currency), driven by growth in Paid Content and IP Adaptations but partially offset by Advertising declines; however, net loss widened to $373.4M from $152.9M due to goodwill impairments, and Adjusted EBITDA declined to $19.4M from $68.0M amid lower gross profit and higher marketing expenses. Q4 2025 revenue fell 6.3% YoY to $330.7M (-4.1% constant currency), driven by declines in Paid Content, Advertising, and IP Adaptations, though Adjusted EBITDA improved slightly to $0.6M from -$3.5M due to cost controls. The company ended the year with a strong balance sheet featuring ~$582M in cash and cash equivalents and no debt.

• ·Q1 2026 outlook: Revenue $317M-$327M (-1.5% to +1.5% constant currency); Adjusted EBITDA $0M-$5M (margin 0.0%-1.5%).
• ·Cash flow from operations Q4 2025: $7.6M vs $(8.7)M prior year.
• ·Approximately 160 million monthly active users.
• ·Conference call on March 3, 2026 at 4:30 p.m. Eastern Time.
• ·Strategic partnerships established with Disney and Warner Bros. Animation in 2025.

03-03-2026

Vertiv Holdings Co completed a $2.1B senior unsecured notes offering across 10-, 20-, 30-, and 40-year tranches, raising $2.08B in net proceeds used with cash on hand to fully repay its existing secured term loan, and closed a new $2.5B senior unsecured revolving credit facility with a 5-year maturity, replacing the prior $800M asset-based facility. S&P and Moody’s each upgraded Vertiv’s debt ratings by one notch on February 12 and 19, 2026, achieving investment grade status (Baa3/BBB-/BBB- from Moody’s/S&P/Fitch). These transactions extend debt maturities, enhance liquidity, and provide financial flexibility, with no negative impacts on existing commitments, guarantees, or liens reported.

• ·Notes offering split across four tranches with 10-year, 20-year, 30-year, and 40-year maturities.
• ·Vertiv headquartered in Westerville, Ohio, does business in more than 130 countries.

03-03-2026

NextEra Energy, Inc. (NEE) sold $2.3 billion of equity units on March 3, 2026, including the full exercise of the underwriters' overallotment option. Each equity unit provides a 7.375% annual distribution rate, consisting of a stock purchase contract for NEE common stock (priced between $91.99 and $115.00 per share by February 15, 2029) and interests in Series P Debentures (due 2031) and Series Q Debentures (due 2034) issued by NextEra Energy Capital Holdings, Inc. and guaranteed by NEE. No declines or underperformance noted in the filing.

• ·Each Debenture issued in principal amount of $1,000.
• ·Stock purchase contract settlement by no later than February 15, 2029; may use remarketing proceeds if successful.
• ·Equity units registered under Registration Statement Nos. 333-278184, 333-278184-01, 333-278184-02.
• ·Stock purchase price per share range: $91.99 to $115.00.

03-03-2026

Dave Inc. announced the commencement of a private offering of $150 million aggregate principal amount of Convertible Senior Notes due 2031, subject to market and other conditions, offered only to qualified institutional buyers under Rule 144A. Initial purchasers have an option to purchase up to an additional $22.5 million aggregate principal amount within a 13-day settlement period. In connection with the offering, the company expects to enter into privately negotiated capped call transactions with initial purchasers or affiliates.

• ·Notes offered in reliance on Rule 144A for qualified institutional buyers
• ·Option settlement period: 13 days beginning on issuance date
• ·Press release issued pursuant to Rule 135c under the Securities Act

03-03-2026

Jones Lang LaSalle Incorporated (JLL) announced changes to its organizational and financial reporting structure effective January 1, 2026, including elevating Software and Technology Solutions as a fifth business line within Real Estate Management Services, collapsing revenue disaggregation in Leasing Advisory, and simplifying Investment Management revenue into Advisory fees and Incentive and transaction fees. Recast financial results for full years 2023, 2024, and 2025 under the new structure were made available on the investor relations website on March 3, 2026, and attached as Exhibit 99.1. No performance metrics or period-over-period changes were disclosed in this filing.

• ·Initial announcement of organizational change: November 5, 2025
• ·Leasing Advisory change announcement: February 18, 2026
• ·Recast periods covered: full years 2023, 2024, and 2025
• ·Investor relations website: ir.jll.com

03-03-2026

BuzzFeed Media Enterprises, Inc. and its subsidiaries secured consent from Sound Point Agency LLC (Administrative Agent) and Banner Commercial Funding (Cayman) L.P. (Lender) to amend their Credit Agreement by deferring a required $5 million principal loan repayment from February 20, 2026, to March 6, 2026. In consideration, BuzzFeed must pay a $20,000 extension fee by March 2, 2026, with non-payment triggering an immediate Event of Default. This amendment underscores liquidity pressures, as the company could not meet the original deadline.

• ·Credit Agreement originally dated May 23, 2025, with prior amendments on July 31, 2025 (Amendment No. 1) and August 25, 2025 (Amendment No. 2).
• ·Consent letter executed on February 20, 2026; effective upon receipt of executed counterparts and entry into Reporting Agent Engagement Letter.
• ·Governed by New York law; non-waiver of other Credit Agreement provisions.

03-03-2026

Pliant Therapeutics, Inc. entered into an Amendment to its Stockholder Rights Agreement on March 3, 2026, with Computershare Trust Company, N.A., extending the final expiration time of the Rights from 5:00 p.m., New York City time on March 11, 2026, to 5:00 p.m., New York City time on March 11, 2027. The extension is designed to deter open market accumulations that could lead to control without a premium or adequate board review, and was not in response to any specific takeover offer. The Rights may still be redeemed, exchanged, or terminated earlier per the original terms.

03-03-2026

Quanex Building Products Corporation adopted its Fifth Amended and Restated By-Laws, effective February 26, 2026, filed via 8-K on March 3, 2026. The by-laws detail standard governance provisions including registered offices, capital stock issuance and transfers, replacement certificates, and stockholder meeting procedures. They impose strict notice requirements for stockholder proposals and director nominations at annual meetings, such as delivery 90-120 days prior to the anniversary of the prior meeting.

• ·Stockholder notice for annual meeting must be received not later than close of business on 90th day nor earlier than 120th day prior to first anniversary of preceding annual meeting; adjusted if meeting date changes by more than 30 days before or 60 days after anniversary.
• ·If public announcement of annual meeting date is less than 90 days prior, notice due by 10th day following announcement.
• ·Stockholder must update notice within 5 business days after record date regarding ownership, derivatives, and arrangements.

03-03-2026

BrightView Holdings, Inc. held its 2026 Annual Meeting of Stockholders on March 3, 2026, electing eight directors for common stock (e.g., Dale A. Asplund with 131.1M votes for and Jane Okun Bomba with 132.2M votes for) and two directors (Kurtis Barker and Joshua Goldman) for Series A Convertible Preferred Stock with unanimous 500,000 votes for each. While all directors received majority support, significant votes were withheld for James R. Abrahamson (23.5M withheld) and Paul E. Raether (10.3M withheld). Stockholders ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026 with overwhelming support of 139.0M votes for versus 206K against.

• ·Proxy Statement filed with SEC on January 15, 2026
• ·Directors elected for one-year term expiring at 2027 Annual Meeting
• ·5,348 abstentions on auditor ratification

03-03-2026

QuickLogic reported Q4 FY25 revenue of $3.7M, down 34.2% YoY from $5.7M but up 84.0% QoQ from $2.0M, with full-year FY25 revenue at $13.8M, a 30% decline from $19.7M. While new product revenue grew 198.6% QoQ to $2.8M, it fell 38.5% YoY, mature products declined slightly YoY to $0.9M, and GAAP gross margin dropped sharply to 18.1% from 62.7% YoY amid widening GAAP net loss of $6.0M. Positive highlights include expanding the U.S. SRH FPGA program ceiling to $89M and securing a $13M contract tranche.

• ·Cash and equivalents declined to $18.8M from $21.9M year-end FY24.
• ·Revolving line of credit reduced to $15.0M from $18.0M year-end FY24.
• ·GAAP operating expenses increased to $4.2M in Q4 FY25 from $3.4M YoY.
• ·Full year FY25 GAAP net loss $14.8M vs $3.8M in FY24.

03-03-2026

Boston Scientific Corporation discussed its 10% to 11% organic growth guidance for 2026 at TD Cowen’s 46th Annual Health Care Conference, affirming confidence despite challenging year-over-year comps, supported by acquisitions including Penumbra, Nalu, and Valencia, and strong performance in ICTx, interventional oncology, endoscopy, neuromodulation, and PI businesses. The Penumbra acquisition is expected to enhance Boston Scientific's neurovascular and thrombectomy capabilities, with Penumbra operating as a stand-alone unit under the cardiovascular group to leverage global scale, relationships, and supply chain synergies. Regulatory approval process is ongoing with no specific closing timeline provided.

• ·Penumbra to be integrated as stand-alone business under ICTx PI vascular group post-closing.
• ·Conference held on March 3, 2026.
• ·Penumbra's Q4 results described as strong, with focus on US market and expansion opportunities outside US.

03-03-2026

On February 25, 2026, the Compensation Committee of Firefly Aerospace Inc. adopted the Executive Severance Plan to standardize severance benefits for eligible executive officers and management employees upon qualifying terminations without Cause or for Good Reason. The plan provides lump sum payments equal to annual base salary (or 2x for CEO during Change in Control Protection Period), prorated or full target bonuses, and COBRA subsidies for 1 year (or 2 years for CEO in CIC), along with equity vesting acceleration. No specific financial amounts or performance metrics were disclosed.

• ·Requires at least 1 full year of continuous service for severance eligibility (waived during 24-month Change in Control Protection Period).
• ·Death or Disability termination provides annual base salary plus prorated target bonus (pre-June 30) or performance-based bonus (post-June 30), and 1 year COBRA.
• ·Equity vesting: 1-year acceleration for time-based RSUs outside CIC; full vesting of all unvested awards in CIC or death.
• ·Subject to general release of claims; no tax gross-up, with 280G Excise Tax best-net-after-tax reduction.

03-03-2026

Quipt Home Medical Corp. convened a special shareholder meeting on March 3, 2026, approving the Arrangement Resolution for the arrangement agreement dated December 14, 2025, with 98.9% of votes cast in favor (28,737,677 for vs. 319,623 against) out of 29,672,136 shares voted, representing 66.93% turnout of 44,329,972 outstanding shares. After excluding votes per Multilateral Instrument 61-101, approval stood at 98.68% (23,929,010 for). No abstentions or broker non-votes were recorded.

• ·Record date for meeting: January 22, 2026
• ·Interim order from Supreme Court of British Columbia: January 23, 2026
• ·Definitive management information circular filed with SEC: February 4, 2026
• ·Press release attached as Exhibit 99.1

03-03-2026

FirstCash Holdings, Inc. announced the availability of its most recent investor presentation on its corporate website (investors.firstcash.com), furnished as Exhibit 99.1 to this Form 8-K filed on March 3, 2026. The presentation is incorporated by reference in Item 7.01 but is 'furnished' and not deemed 'filed' for liability purposes. No specific financial metrics or performance data are disclosed in the filing itself.

• ·Securities registered: Common Stock, par value $0.01 per share (FCFS) on The Nasdaq Stock Market.
• ·Principal executive offices: 1600 West 7th Street, Fort Worth, Texas 76102.
• ·Telephone: (817) 335-1100.

03-03-2026

Rogers Corporation announced the departure of Michael Webb, its Senior Vice President and Chief Administrative Officer, effective March 13, 2026. Mr. Webb will receive severance payments and benefits under the Company’s Executive Severance Plan, contingent on executing a general release of claims and complying with restrictive covenants including non-competition and non-solicitation. The 8-K filing, dated March 3, 2026, was signed by Laura Russell, Senior Vice President, Chief Financial Officer, and Treasurer.

• ·Event reported date: March 2, 2026
• ·Filing date: March 3, 2026

03-03-2026

Arq, Inc. entered into the Fourth Amendment to its Revolving Credit Agreement on February 27, 2026, with MidCap Funding IV Trust as agent, extending prior amendments to borrowing availability calculations and temporarily reducing the minimum liquidity covenant to $2.0M from December 10, 2025, through March 31, 2026, before increasing it to $5.0M thereafter. This provides short-term covenant relief amid ongoing amendments (previously on December 27, 2024; May 6, 2025; December 9, 2025; and January 28, 2026), suggesting potential liquidity pressures.

• ·Prior amendments to Revolving Credit Agreement dated Dec 27, 2024; May 6, 2025; Dec 9, 2025; Jan 28, 2026
• ·Agreement covers Arq, Inc. and certain subsidiaries as guarantors

03-03-2026

Jacobs Solutions Inc. completed a $1.3B senior notes offering on March 3, 2026, issuing $800M of 4.750% notes due 2031 and $500M of 5.375% notes due 2036, fully guaranteed by subsidiary Jacobs Engineering Group Inc. Proceeds will finance the acquisition of remaining shares in PA Consulting Group Limited, with interim use to repay revolving credit and term loan facilities; if the acquisition fails, proceeds will repay debt and support general corporate purposes. The notes rank as senior unsecured obligations with standard redemption and covenant terms, including a change of control repurchase at 101%.

• ·Interest payable semi-annually on March 3 and September 3, commencing September 3, 2026.
• ·Par Call Date: February 3, 2031 for 2031 Notes; December 3, 2035 for 2036 Notes.
• ·Indenture covenants limit secured indebtedness, sale-leaseback transactions, and mergers.
• ·Guarantees releasable if Guarantor's 2033/2028 notes ≤ $300M and related credit facility guarantees released.

03-03-2026

On March 3, 2026, the board of directors of American Integrity Insurance Group, Inc. announced that its first 2026 Annual Meeting of Stockholders will be held on June 11, 2026, with a record date of April 13, 2026. Stockholders seeking to include proposals in the proxy materials under Rule 14a-8, or submit nominations or proposals under the bylaws or universal proxy rules, must do so by March 12, 2026, to the company's Secretary in Tampa, FL. Meeting details will be in the forthcoming proxy statement.

• ·Company address: 5426 Bay Center Drive, Suite 600, Tampa, FL 33609
• ·Telephone: (813) 880-7000
• ·Trading symbol: AII (Common Stock, $0.001 par value) on NYSE
• ·Emerging growth company status confirmed
• ·This is the company's first annual meeting of stockholders

03-03-2026

Rimini Street, Inc.'s Compensation Committee approved the 2026 Long-Term Incentive Plan effective March 2, 2026, granting PSUs, RSUs, and stock options to named executive officers with targeted grant values ranging from $300,000 to $2.64M for CEO Seth A. Ravin. PSUs are tied to 2026 Adjusted EBITDA and total revenue performance over a one-year period, with all awards vesting in three equal annual installments subject to continued service. No performance declines or flat metrics are reported, as this filing focuses solely on compensatory arrangements.

• ·PSUs earned based on average of Adjusted EBITDA and Total Revenue payout factors, ranging from 0% to 200% of target.
• ·Performance period for PSUs: January 1, 2026 to December 31, 2026.
• ·Vesting for PSUs, RSUs, and Stock Options: three equal annual installments on 1st, 2nd, and 3rd anniversaries of March 2, 2026.
• ·Stock Options for non-CEO NEOs are incentive stock options; Ravin received non-qualified options due to >10% ownership.

03-03-2026

Ventyx Biosciences, Inc. held a special shareholder meeting on March 3, 2026, where Proposal 1 to approve the Merger Agreement with Eli Lilly and Company received overwhelming support with 44,176,785 votes FOR (96.4% of votes cast) versus 1,572,592 AGAINST out of 45,810,746 shares present or by proxy. Proposal 2 on advisory executive compensation approval also passed with 43,789,693 FOR (95.6%). As of the January 21, 2026 record date, 71,760,778 common shares were outstanding.

• ·Merger Agreement dated January 7, 2026; special meeting at 10:00 a.m. Pacific time on March 3, 2026.
• ·Proxy statement dated February 2, 2026, amended February 23, 2026.
• ·Proposal 3 (adjournment) rendered moot and not presented.

03-03-2026

NeOnc Technologies Holdings, Inc. (NTHI) entered into Securities Purchase Agreements to issue and sell up to 2,222,222 shares of common stock at $7.20 per share and warrants to purchase the same number at $9.00 exercise price. Closings raised $10M from 1,388,888 shares/warrants to one institutional investor, $621,804 from 86,361 shares/warrants to three investors, and $1.45M from 201,390 shares/warrants to four investors, with net proceeds for working capital. The company will file a resale registration statement within 10 days after its Form 10-K for the year ended December 31, 2025.

• ·First Securities Purchase Agreement dated January 29, 2026, terminated January 31, 2026.
• ·Second Securities Purchase Agreement dated February 24, 2026, terminated February 28, 2026.
• ·Securities issued pursuant to Section 4(a)(2) exemption under Securities Act.
• ·Exhibits include Form of Warrant (4.1) and Form of Securities Purchase Agreement (10.1).

03-03-2026

Babcock & Wilcox Enterprises, Inc. executed the Tenth Amendment to its Credit Agreement and Security Agreement with Axos Bank on February 25, 2026, amending the borrowing base to 90% of Eligible Trade Receivables, setting NOLV Percentage at 30.78%, extending the Maturity Date to January 18, 2028, and imposing strict cash management rules including 90-day transfers to Axos Bank and balance limits on accounts such as Canadian Project Accounts ($15M aggregate) and Chanute Operating Account ($5M). The amendment mandates redemption of December 2026 Unsecured Notes by November 30, 2026, following prior full repayment of February 2026 Unsecured Notes, while noting entity name changes including B. Riley Financial, Inc. to BRC Group Holdings, Inc. and dissolutions of SOFCO-EFS Holdings LLC and B&W PGG Luxembourg Canada Holdings.

• ·Unrestricted cash outside Axos Bank capped at $15M aggregate, with no more than $5M in non-controlled accounts, Canadian Project Accounts, or Chanute Operating Account.
• ·Within 90 days of February 25, 2026, transfer substantially all USD deposits from Canadian Project Accounts and Chanute Operating Account to Axos Bank.
• ·Notice of redemption for December 2026 Unsecured Notes required by October 30, 2026, with full satisfaction by November 30, 2026.
• ·Aggregate balance of Chanute Operating Account and Canadian Project Accounts not to exceed $15M at any time.

03-03-2026

Selling stockholders are offering 14.3 million shares of NRG Energy, Inc. common stock at $164 per share, totaling approximately $2.345B in gross proceeds, with underwriters holding an option for an additional 2.145 million shares. Concurrently, NRG has agreed to repurchase $300M of its common stock from the selling stockholders at the public offering price, to be held as treasury shares, signaling management confidence despite the offering price being about 6.6% below the March 1, 2026 closing price of $175.58 per share. NRG will not receive proceeds from the share sale but conditions the repurchase on the offering's completion.

• ·Closing of offering and share repurchase expected on or about March 4, 2026.
• ·Underwriters' option exercisable within 30 days from March 2, 2026.
• ·Share repurchase conditioned on offering completion; offering not conditioned on repurchase.
• ·Common stock listed on NYSE and NYSE Texas under ticker 'NRG'.

03-03-2026

Cryoport reported FY 2025 revenue of $176.2 million, up 12% YoY from $156.8 million, driven by 18% growth in Life Sciences Services (including 22% in BioStorage/BioServices) and 29% increase in commercial cell and gene therapy revenue to $33.4 million; however, Life Sciences Products grew only 7% YoY (2% in Q4), and adjusted EBITDA from continuing operations remained negative at -$5.8 million despite a $12 million YoY improvement. The company supported a record 760 global clinical trials and 20 commercial therapies, and provided FY 2026 revenue guidance of $190-194 million (8-10% growth). Gross margins improved to 47.1% from 44.4%, but losses from continuing operations totaled $34.0 million.

• ·Supported 86 Phase 3 clinical trials as of Dec 31, 2025 (up from 81 in 2024).
• ·Q4 2025 total gross margin 47.8% (up from 47.0% YoY); FY 2025 47.1% (up from 44.4%).
• ·Loss from continuing operations FY 2025: $34.0M (improved from $104.7M in 2024).
• ·Divestiture of CRYOPDP to DHL on June 11, 2025, contributed $112.3M net to discontinued operations.
• ·10-K filing expected March 6, 2026.
• ·$63.9M remaining share repurchase authorization.

03-03-2026

On February 27, 2026, the Compensation Committee of CVRx, Inc.'s Board of Directors approved incremental performance stock units (PSUs) to all executive officers, valued at three-fourths of their fiscal 2026 annual long-term incentives, tied to a competitively sensitive cumulative revenue goal for the fiscal 2026-2027 performance period. The PSUs can vest between 50% at threshold performance and 200% at maximum, with 50% settling upon certification post-period and the remaining 50% on December 31, 2028, subject to continued employment. The awards aim to retain executives amid criticality of near-term revenue objectives.

• ·PSUs convert to time-based RSUs at greater of target or actual performance upon change in control.
• ·Vesting includes provisions for accelerated vesting on death, disability, termination without cause, or double-trigger change in control.
• ·Form of PSU Agreement filed as Exhibit 10.1.

03-03-2026

Ring Energy, Inc. appointed Rocky Kwon as Chief Accounting Officer and principal accounting officer on March 1, 2026, alongside his ongoing roles as Vice President and Principal Financial Officer. This appointment coincides with Sundip 'Sonu' S. Johl starting as Executive Vice President and Chief Financial Officer on February 27, 2026, concluding Kwon's interim CFO tenure. The move ensures continuity in the finance leadership with an experienced internal promotee.

• ·Rocky Kwon has served as Vice President of Accounting and Assistant Treasurer since March 2025, Controller since July 2021, and Interim Chief Financial Officer since September 2025.
• ·Prior to joining Ring Energy, Rocky Kwon was Assistant Controller at Earthstone Energy, Inc.
• ·No family relationships between Mr. Kwon and any directors or executive officers; no related party transactions under Item 404(a) of Regulation S-K.

03-03-2026

Monroe Capital Corporation (MRCC) is urging shareholders to vote FOR proposals at a special meeting on March 13, 2026, approving an asset sale to Monroe Capital Income Plus Corporation (MCIP) and a subsequent merger with Horizon Technology Finance Corporation (HRZN), contingent on each other. The transactions are expected to enhance scale with approximately $160M additional equity capital (based on September 30, 2025 financials), resulting in over $475M net assets for the combined HRZN, improved liquidity, neutral-to-accretive returns, and $4M advisory fee waivers by Horizon Technology Finance Management LLC over four post-closing quarters. While benefits are highlighted, forward-looking statements note risks including failure to close, regulatory hurdles, and litigation.

• ·Special shareholder meeting: March 13, 2026 at 2:30 p.m. ET (virtual at www.virtualshareholdermeeting.com/MRCC2025SM2)
• ·Financials basis: September 30, 2025
• ·Fee waiver details: up to $1M per quarter, not exceeding fees earned by HTFM each quarter
• ·Related SEC filings: Registration Statement File No. 333-290114; Joint Proxy Statement

03-03-2026

Cumberland Pharmaceuticals reported fourth quarter 2025 net revenues of $13.7 million, a 31% increase YoY, and full-year 2025 net revenues of $44.5 million, up 18% YoY, meeting their double-digit growth target. The company improved to adjusted earnings of $1.7 million for the year (up $2.7 million YoY) and generated $4.9 million in cash flow from operations (up $5.5 million YoY), while reducing debt by $10 million. However, it still posted a net loss of $2.9 million for 2025, an improvement of $3.6 million from the prior year.

• ·Vibativ approved in China (Feb 2025, exclusive with SciClone), launched in Saudi Arabia (Sep 2025, exclusive with Tabuk), approved in Mexico (Oct 2025, exclusive with PiSA).
• ·Co-commercialization agreement with RedHill Biopharma for Talicia (Oct 2025); Cumberland shares net revenues equally.
• ·Caldolor received permanent CMS J-code J1741 (Dec 2025) for reimbursement.
• ·Credit facility debt reduced by $10M from end of 2024.

03-03-2026

CVR Partners, LP disclosed the death of independent director Brian A. Goebel on February 20, 2026, reducing the Board to five members (two independent) and the Audit Committee to two independent members, causing non-compliance with NYSE Listed Company Manual Section 303A.07(a), which requires at least three independent audit committee members. The Partnership notified NYSE on February 25, 2026, and received formal notice of non-compliance on March 3, 2026. The company has begun searching for a replacement independent director to regain compliance promptly.

• ·Mr. Goebel joined the Board in October 2025.
• ·Compliance to be regained upon appointing a new independent Audit Committee member meeting NYSE and SEC independence requirements.
• ·Principal executive offices: 2277 Plaza Drive, Suite 500, Sugar Land, Texas 77479; Phone: (281) 207-3200.

03-03-2026

Energy Fuels Inc. announced on February 26, 2026, that current CEO Mark Chalmers will retire from his CEO and Director roles effective April 15, 2026, consistent with planned succession, and will serve as a consultant for two years thereafter. Concurrently, President Ross Bhappu will be appointed as President, CEO, and Director effective the same date. The transition is smooth with no disagreements noted, and Bhappu brings over 35 years of mining experience.

• ·Bhappu originally appointed President effective August 4, 2025; employment agreement dated July 30, 2025.
• ·Chalmers' resignation from Board not due to any disagreement with Company operations, policies, or practices.
• ·No family relationships or disclosable transactions under Item 404(a) for Bhappu.
• ·Filing date: March 3, 2026; earliest event date referenced: February 25, 2026.

03-03-2026

FingerMotion, Inc. held its Annual Meeting of Stockholders on February 26, 2026, with 27,126,232 shares (44.26% quorum of 61,281,308 outstanding shares) present; all proposals passed, including election of six directors with support from 82.56% (lowest for Yew Poh Leong) to 99.00%, auditor ratification at 98.86%, and advisory approval of executive compensation at 93.03%. Following the meeting, the Board re-appointed Martin Shen as President and CEO and Yew Hon Lee as CFO, Secretary, and Treasurer. Broker non-votes totaled 13,622,994 shares for director and compensation votes.

• ·Record date for AGM: January 14, 2026
• ·Fiscal year for auditor appointment: ending February 28, 2025
• ·News release issued: March 2, 2026 (Exhibit 99.1)
• ·17.44% withheld votes for Yew Poh Leong (highest withheld)

03-03-2026

On February 27, 2026, Synergy CHC Corp. was notified by Gravity Pharma General Trading LLC of the termination ab initio of the Brand License Agreement dated March 31, 2025 (as amended June 30, 2025), which granted exclusive rights to market FOCUSfactor and Flat Tummy Co. products in the UAE and Turkey in exchange for a $2.9M license fee previously recognized as revenue. This termination voids the agreement from inception, likely requiring revenue reversal. The Company plans to continue pursuing product registration and marketing in the territory.

• ·Territory covered by agreement: United Arab Emirates and Turkey

03-03-2026

ClearThink 1 Acquisition Corp., a Cayman Islands-incorporated SPAC, consummated its IPO on February 25, 2026, selling 12,500,000 units at $10.00 each, generating $125M in gross proceeds deposited into a trust account along with private placement funds from ClearThink 1 Sponsor LLC. On February 26, 2026, the underwriter partially exercised its over-allotment option for 15,000 additional units, adding $150,000 to the trust. An audited balance sheet as of February 25, 2026, is attached as Exhibit 99.1.

• ·Securities traded on Nasdaq Stock Market LLC.
• ·Company address: 150 E. Palmetto Park Road, Suite 202, Boca Raton, Florida 33432.
• ·Telephone: (561) 358-3696.